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Abstract 
 
Background: Venous thromboembolism (VTE), comprising the conditions of 
deep vein thrombosis (DVT) and pulmonary embolism (PE), is a common acute 
cardiovascular event associated with increased long-term morbidity, functional 
disability, all-cause mortality, and high rates of recurrence. Major advances in 
identification, prophylaxis, and treatment over the past 3-decades have likely 
changed its clinical epidemiology. However, there are little published data 
describing contemporary, population-based, trends in VTE prevention and 
management. 
Objectives: To examine recent trends in the epidemiology of clinically 
recognized VTE and assess the risk of recurrence after a first acute episode of 
VTE. 
Methods: We used population-based surveillance to monitor trends in acute VTE 
among residents of the Worcester, Massachusetts, metropolitan statistical area 
(WMSA) from 1985 through 2009, including in-hospital and ambulatory settings.  
Results: Among  5,025 WMSA residents diagnosed with acute PE and/or lower-
extremity DVT between 1985 and 2009 (mean age = 65 years), 46% were men 
and 95% were white. Age- and sex-adjusted annual event rates (per 100, 000) of 
clinically recognized acute first-time and recurrent VTE was 142 overall, 
increasing from 112 in 1985/86 to 168 in 2009, due primarily to increases in PE 
occurrence. During this period, non-invasive diagnostic VTE testing increased, 
vi 
 
while treatment shifted from the  in-hospital (chiefly with warfarin and 
unfractionated heparin) to out-patient setting (chiefly with low-molecular-weight 
heparins and newer anticoagulants). Among those with community-presenting 
first-time VTE, subsequent 3-year cumulative event rates of key outcomes 
decreased from 1999 to 2009, including all-cause mortality (41% to 26%), major 
bleeding episodes (12% to 6%), and recurrent VTE (17% to 9%). Active-cancer 
(with or without chemotherapy), a hypercoagulable state, varicose vein stripping, 
and Inferior vena cava filter placement were independent predictors of 
recurrence during short- (3-month) and long-term (3-year) follow-up after a first 
acute episode of VTE. We developed risk score calculators for VTE recurrence 
based on a 3-month prognostic model for all patients and separately for patients 
without active cancer.   
Conclusions: Despite advances in identification, prophylaxis, and treatment 
between 1985 and 2009, the disease burden from VTE in residents of central 
Massachusetts remains high, with increasing annual events. Declines in the 
frequency of major adverse outcomes between 1999 and 2009 were reassuring. 
Still, mortality, major bleeding, and recurrence rates remained high, suggesting 
opportunities for improved prevention and treatment. Clinicians may be able to 
use the identified predictors of recurrence and risk score calculators to estimate 
the risk of VTE recurrence and tailor outpatient treatments to individual patients. 
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Chapter I. Introduction 
 
1.1 Specific aims 
Venous thromboembolism (VTE), comprising the conditions of deep vein 
thrombosis (DVT) and pulmonary embolism (PE), is associated with increased 
long-term morbidity, functional disability, and mortality.1 VTE has been estimated 
to be the third most common cardiovascular disorder in American adults after the 
acute coronary syndromes and ischemic stroke.2 Estimates from observational 
studies conducted more than a decade ago suggested that there are between 
150,000 to 300,000 new cases of clinically recognized VTE, and 100,000 to 
200,000 VTE-associated deaths, that occur annually in the United States.3-5 
However, recent clinical data on the descriptive epidemiology of VTE are limited.6 
The need for better estimates of the magnitude of VTE was the impetus for two 
National Institutes of Health-funded, population-based, epidemiologic studies 
carried out in residents of the Worcester Metropolitan Statistical Area (WMSA), 
namely the Worcester DVT Study (1986-1990: Cohort-I) and the Worcester VTE 
Study (1999-2009: Cohort-II).3,7 Both studies employed  population-based 
surveillance methods to monitor trends in the incidence, management strategies, 
recurrence, and case-fatality rates of VTE among residents of the WMSA. These 
studies provide a solid foundation to describe the clinical epidemiology of VTE in 
residents of central Massachusetts, and changes over time therein. 
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During the past three decades, there have been major advances in 
identifying patients at increased risk for VTE, and in the development of improved 
prophylaxis, diagnostic, and treatment strategies.6 8-13 These advances have 
likely changed the clinical epidemiology of VTE. In addition, with recent changes 
in health care delivery, such as decreasing lengths of acute hospitalization and 
increasing treatment in the outpatient setting,14-15 patients are being sent home 
earlier with major ongoing risk factors for VTE. It is possible that an increasing 
proportion of VTE is being shifted from the hospital setting to the community 
setting, and a majority of patients will now be treated as outpatients due to 
advances in therapeutic strategies.16 Therefore, it remains of considerable 
importance to examine secular trends in the clinical epidemiology of VTE, 
particularly among patients with episodes of VTE that have occurred in the 
broader community setting.   
VTE is a disease with multiple risk factors and this condition is associated 
with high rates of recurrence.1, 11 Despite ongoing advances in the therapeutic 
management of patients with VTE, recurrence is common during the first 2-3 
years after the development of this thromboembolic disorder.17-19 Accordingly, 
identifying risk factors associated with VTE recurrence will hopefully lead to more 
effective VTE treatment. 
The primary goal of this dissertation project is to describe multi-decade 
long trends in the magnitude, management, and short- and long-term outcomes 
of VTE from a broad population-based perspective among residents of central 
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Massachusetts. In addition, I have developed a risk assessment model (RAM) to 
estimate the risk of recurrent VTE within 3 years after a first acute episode. To 
accomplish these objectives, I used data (~ 5000 VTE cases) from the Worcester 
VTE Study Cohort-I and Cohort-II. The objectives of my dissertation project 
include the following specific aims: 
Aim 1: Describe secular trends (1985–2009) in VTE prevalence and 
incidence rates, associated patient characteristics, type of VTE events, 
occurrence settings, and diagnostic methods utilized. 
H1a: The proportion of patients who develop VTE in the community setting has 
increased during the years under study. 
H1b: The proportion of all VTE patients who underwent an objective diagnostic 
test to confirm the presence of VTE has increased over time. 
H1c: The proportion of patients with objectively diagnosed VTE who underwent a     
non-invasive confirmatory test has increased between 1985 and 2009. 
Aim 2: Examine recent decade long trends (1999–2009) in the clinical 
management and long-term outcomes among patients with a first episode 
of VTE that developed in the community setting. 
H2a: There has been an improvement over time in the use of prior VTE 
prophylaxis. 
H2b: There has been an increased use of low molecular weight heparin over time 
and in the proportion of patients who receive this treatment in the outpatient 
setting. 
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Aim 3: Develop a RAM to predict the risk of VTE recurrence within 3 years 
after a first episode of VTE. 
The findings of this dissertation project provide relatively contemporary 
insights into the clinical epidemiology of VTE from a population-based 
perspective and provide important data on the evolution and outcomes of 
diagnostic and therapeutic strategies used in the management of VTE. This 
information is sorely lacking in the published literature, which may be utilized for 
the design and testing of interventions to enhance current management practices 
with the goal of favorably influencing the long-term outcomes of patients with 
VTE. In addition, following independent validation, the new RAM developed as 
part of this dissertation to predict recurrent episodes of VTE may serve as a 
clinical decision support tool to guide clinicians to deliver more effective VTE 
treatment. 
 
1.2 Significance: disease burden 
Venous thromboembolism (VTE) (deep vein thrombosis [DVT] and/or pulmonary 
embolism [PE]) is associated with increased long-term morbidity, functional 
disability, and mortality.1 VTE has been estimated to be the third most common 
cardiovascular disorder in adult Americans after the acute coronary syndromes 
and ischemic stroke.2 PE remains a leading cause of death in western countries 
following hospitalization for childbirth, major surgery, and acute medical 
conditions.1 Estimates from observational studies conducted more than a decade 
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ago suggested that there are between 150,000 to 300,000 new cases of clinically 
recognized VTE, and 100,000 to 200,000 VTE-associated deaths, that occur 
annually in the United States.3-5  
DVT occurs when the deep veins carrying blood back to the heart develop 
one or more large clots, usually in the lower extremities.1 Leg pain and swelling 
may result, but the most serious complication associated with DVT results in a 
potentially life-threatening PE when part or all of the thrombus breaks loose and 
embolizes to the pulmonary vessels.1 Symptoms of PE include chest pain and 
shortness of breath, leading to sudden death in severe cases.1 Late sequelae of 
DVT are a source of substantial morbidity and include venous stasis syndrome, 
venous leg ulcers, and chronic thromboembolic pulmonary hypertension,1 which 
have been shown to negatively impact patient’s long-term quality of life.20-22 In 
addition, patients with a history of VTE are nearly eight times more likely to 
develop another episode of VTE as compared to patients without a history of 
DVT or PE.23  
In addition to the clinical impact of VTE, the economic burden of this 
disease is considerable.24-26 Direct medical costs for the treatment of patients 
with nonfatal VTE were recently estimated to be between 6-8 billion dollars in the 
United States.6 25 
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1.3 Significance: clinical epidemiology of VTE 
Knowledge of the clinical epidemiology of VTE comes primarily from three 
National Institutes of Health-funded, population-based, observational studies in 
the United States.3, 5, 7 The first two, based in Worcester, Massachusetts (MA), 
include the Worcester DVT Study (1986-1990: Cohort-I)3 and the Worcester VTE 
Study (1999-2009: Cohort-II).7  A third study, the Rochester Epidemiology 
Project, is based in Olmsted County, Minnesota.5 These studies provide the best 
data to assess the clinical epidemiology of VTE in United States, and changes 
over time therein, from the more generalizable perspective of a population-based 
investigation. 
Investigators from the Rochester Epidemiology Project retrospectively 
reviewed the inpatient and outpatient medical records from a population-based 
inception cohort of 2,218 patients who resided in Olmsted County, Minnesota 
and who experienced a first episode of DVT or PE during the 25-year period 
between 1966 and 1990.5 The overall age- and sex-adjusted  annual incidence 
rate of VTE was 117 per 100,000 population.5 Overall, the incidence rates of first 
episodes of VTE were relatively high between 1966 and 1976, declined by 30% 
between 1977 and 1979, and remained relatively stable from 1980 through 
1990.5 Based on the Worcester VTE Study Cohort-I, during the 18-month period 
from July, 1985 to December, 1986, the crude annual incidence rate of first 
episodes of VTE was 71 per 100,000 population.3 Results of the Worcester VTE 
Study Cohort-II indicated that the age- and sex-adjusted annual incidence rates 
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of first episodes of VTE (including upper-extremity DVT) were 104, 116, and 117 
per 100,000 population during 1999, 2001, and 2003, respectively.7,27 However, 
long-term trends (1985 – 2009) in the Worcester VTE studies have not been 
assessed.  
In 1884, Rudolph Virchow first proposed that thrombosis was the result of 
at least 1 of 3 underlying etiologic factors: vascular endothelial damage, stasis of 
blood flow, and blood hypercoagulability.23 Previous publications based on the 
Rochester Epidemiology Project, early year cohorts of the Worcester VTE 
studies, and other epidemiologic studies indicated that risk factors for  VTE 
included male sex, increasing age, obesity, malignancy, prolonged immobility, 
neurological disease with leg paresis, central vein catheterization or receipt of a 
transvenous pacemaker, varicose veins, myocardial infarction, respiratory failure, 
congestive heart failure, pregnancy and the puerperium, oral contraceptives, 
antiphospholipid antibody syndrome, an inherited thrombophilic condition, 
persistently increased plasma fibrin D-dimer levels, surgery, trauma, hospital or 
nursing home confinement, and prior VTE.1, 23, 28 29-37 In particular, the incidence 
rates of VTE increase markedly with advancing age.1, 3, 19, 23, 28 However, current 
estimates of the clinical epidemiology of VTE are lacking, particularly 
identification of elevated VTE risk at an individual patient level.6 
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1.4 Significance: trends in the clinical management of VTE 
There have been major advances in identifying patients at increased risk 
for VTE,  in the development of improved prophylaxis, and in diagnostic and 
treatment strategies,6 8-13 which have likely changed the descriptive clinical 
epidemiology of VTE. 
The evolution of computer imaging technology led to a change in VTE 
diagnostic strategies. The common diagnostic tests were shifting from invasive 
imaging (venography and angiography) in the 1980’s to the use of noninvasive 
imaging tests (compression ultrasound imaging, lung scan and computed 
tomography imaging) in the 1990’s. During recent years, the combination of 
noninvasive imaging, D-dimer measurement, and a clinical probability 
assessment have become common diagnostic strategies for VTE,8-10 whose 
increasing use could have impacted the reported event rates of VTE.  
The introduction of the subcutaneous low molecular weight heparins 
(LMWHs) in the 1990’s as an alternative to the treatment requiring dosing 
monitoring (intravenous unfractionated heparin [UFH] and Vitamin-K antagonists) 
has dramatically changed the manner in which the initial care of patients with 
VTE is presently carried out.38-42 Recently, several orally active small molecules 
have been evaluated in the treatment of VTE, including a direct thrombin inhibitor 
and several direct Factor Xa inhibitors.16 Other novel oral agents are also in 
development for VTE treatment.16  
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In addition, growing awareness of VTE as an important public health 
problem served as the impetus for several revisions of evidence-based clinical 
practice guidelines for appropriate VTE prevention and treatment.11-13 6, 43 A VTE 
quality measure was selected as a core measure set for use in the Joint 
Commission’s ORYX program (performance measurement and improvement 
initiative) in the 2000’s.43 Each of these practice and guideline recommendations 
could have altered physicians clinical practice patterns. 
Therefore, I propose to assess 25-year trends (1985-2009) in VTE event 
rates, associated patient characteristics, and diagnostic methods utilized by 
examining data from the Worcester VTE Study Cohort-I and Cohort-II (including 
unpublished findings from the 1988/89, 2005, 2007,  and 2009 cohorts). This 
research may provide new insights into relatively recent changes in the clinical 
epidemiology of VTE, reflecting the impact of rapidly evolving clinical practices in 
the management of VTE. 
 
1.5 Significance: VTE in the community setting 
 Although hospitalized patients are at particularly high risk for developing 
VTE,1, 11 data from early findings of the Worcester VTE Study cohorts suggested 
that most episodes of VTE occurred in the community setting.44-45 It is notable 
that a substantial proportion of these patients had undergone surgery or 
hospitalization in the preceding 3 months.3, 7, 45 With recent changes in health 
care services, including decreasing lengths of acute hospitalization that postpone 
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medical diagnosis and treatment to the outpatient setting,14-15 patients are being 
sent home earlier with potential risk factors for VTE. It is possible that an 
increasing proportion of VTE is being shifted from the hospital to the community 
setting. In addition, recent advances in different therapeutic strategies have 
made it possible to treat most patients on an outpatient basis for longer periods 
of time.16  
 Therefore, it becomes increasingly important to investigate recent decade 
long trends (1999-2009) in the clinical management (prior VTE prevention, in-
hospital and/or outpatient VTE treatment) and long-term outcomes among 
patients with a first episode of VTE that occurred in the community setting. This 
research may provide new insights into the profile and management of patients 
who experience VTE in the community setting, ultimately representing a 
significant proportion of failures in VTE prevention after a preceding 
hospitalization. The findings may generate testable hypotheses and subsequent 
investigations that will ultimately improve VTE prevention and its treatment. 
 
1.6 Significance: VTE recurrence 
VTE is a disease with multiple risk factors, which tends to recur.1, 11 
Despite therapeutic advances in the management of patients with VTE, the 
cumulative incidence rates of recurrent VTE remain high during the first 2-3 years 
after the development of this thromboembolic disorder.17-19 Accordingly, 
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identifying risk factors associated with VTE recurrence may lead to more 
effective VTE treatment. 
In current practice, the optimal duration of anticoagulation in patients with 
VTE is based on balancing the risks of recurrence and bleeding during the three 
month period during which anticoagulation therapy is prescribed following an 
index episode of VTE.46 The decision as to continue or discontinue 
anticoagulation after this period should be individually tailored and balanced 
against the risk of hemorrhage.46 Current practice guidelines for the management 
of VTE shift the focus away from laboratory testing and place stronger emphasis 
on identifying clinical factors when making treatment decisions.47-48 Despite 
substantial progress in identifying the determinants of recurrent VTE,49-50 
prediction of elevated risk in an individual patient is often not feasible in routine 
care. Therefore, it would advance patient care to develop a robust risk 
assessment model (RAM) to identify independent predictors of recurrent 
episodes of VTE by using contemporary and population-based data. This RAM 
could be used as a clinical decision support tool to guide clinicians to deliver 
more effective VTE treatment. 
 
1.7 Innovation 
The findings of this dissertation project may provide contemporary insights 
into the clinical epidemiology of VTE from a population-based perspective and 
may provide important data on the evolution and outcomes of diagnostic and 
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therapeutic strategies used in the contemporary management of VTE. This 
information is sorely lacking in the published literature. The findings of this 
dissertation project may be instrumental in identifying VTE patients at increased 
risk for the underutilization of specific therapies as well as for early and more 
long-term adverse outcomes. This information may set the stage for the design 
and testing of interventions to correct deficiencies in current management 
practices with the goal of favorably influencing the long-term outcomes of 
patients with VTE. In addition, following independent validation, the new RAM to 
predict recurrent episodes of VTE may serve as a clinical decision support tool to 
guide clinicians to deliver more effective treatment for this increasingly prevalent 
disorder. 
 
1.8 Approach: overview of methods 
The primary goal of this dissertation project is to describe relatively contemporary 
trends in the clinical epidemiology of clinically recognized VTE and the risk of 
recurrent events from a population-based perspective. I used data from two 
National Institutes of Health funded, population-based, epidemiologic studies 
carried out in Worcester, MA, namely the Worcester DVT Study (1985-1990: 
Cohort-I)3 and the Worcester VTE Study (1999-2009: Cohort-II).7 Both studies 
included all cases of VTE occurring among residents of the Worcester 
Metropolitan Statistical Area (WMSA). 
 
13 
 
1.9 Approach: background of Worcester VTE studies 
The Worcester VTE studies employed proven population-based 
surveillance methods to monitor trends in the incidence, management strategies, 
recurrence, and short and long-term (up to 3 years after initial episode of VTE) 
case-fatality rates in residents of the WMSA. Both studies screened all patients 
with a diagnosis of acute DVT and/or PE based on International Classification of 
Diseases Ninth revision (ICD-9) consistent with possible VTE (Table 1.1) 
documented in medical records from all central MA hospitals that provide short-
term care for residents of the WMSA. 
Prior to 1990, in-hospital treatment was standard clinical practice for all 
newly diagnosed cases of acute VTE. Therefore, Cohort-I included all VTE 
patients discharged during two 18-month periods, July 1985 - December 1986 
and July 1988 - December 1989. Quarterly hospital discharge reports were used 
to screen potential patients based on ICD-9 codes listed in Table 1.1, but only 
objectively confirmed (physician documented) cases of VTE were included. 
Cohort-II included hospitalized patients, as well as patients who were not 
admitted to central MA hospitals, but were diagnosed with VTE based on the 
results of an outpatient, emergency department, radiology department, or 
diagnostic laboratory encounter during 1999, 2001, 2003, 2005, 2007, and 2009. 
In addition, the logs and/or computerized billing lists of patients evaluated in 
greater Worcester ultrasound departments were screened to identify potential 
cases of VTE that may have been missed due to coding errors, and to identify 
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patients referred directly from outside physicians’ offices, rehabilitation facilities, 
and nursing homes for testing who then returned directly to these settings for 
treatment. Data on index and follow-up events were collected at the same time 
when the medical records were reviewed, approximately three-years after the 
index event (i.e., the length of follow-up is 3 years for all included patients). 
National and statewide death registries were reviewed on an annual basis to 
ascertain the survival status of all study patients.  
Definition of index VTE  
Although both Worcester VTE studies used ICD-9 codes to screen and identify 
potentially eligible cases of acute DVT and/or PE, there were slight differences in 
ICD-9 codes due to the refining of ICD-9 codes over the years (Table 1.1). In 
addition, Cohort-II included patients with upper extremity DVT.  
In Cohort-I, data were collected only from medical records that included a 
written hospital discharge diagnosis of acute DVT and/or PE. For cases with ICD-
9 codes that were not specific for VTE, particularly the 900 series, cases were 
validated based on lung scan, venography, impedance plethysmography (ICD-9 
codes 88.62, 88.66, 88.68) or pulmonary angiography (ICD-9 code 88.43) test 
results.  
In Cohort-II, cases identified by ICD-9 codes were validated and classified 
by trained data abstractors based on pre-specified criteria as either definite, 
probable, possible, or absent (Table 1.2). The criteria were developed based on 
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a modification of a classification schema proposed by Silverstein et al.5  Only the 
cases identified as definite, probable, and possible were included in Cohort-II.  
Potential cases of recurrent VTE as the index event were classified using 
criteria similar to those used for first-time cases if the patient had a prior VTE 
noted in their medical records. 
Definition of Adverse Events after Index VTE in Cohort-II 
Recurrence was classified using criteria similar to those employed for the 
index event, but required occurrence of thrombosis in a previously uninvolved 
venous (recurrent DVT) or pulmonary segment (recurrent PE). Recurrent VTE 
was classified as the first occurrence of DVT or PE after the index VTE. 
Episodes of major bleeding that may have occurred for patients in the 
study years of 1999, 2001, and 2003 were defined as any episode of bleeding 
requiring transfusion of ≥2 units of packed red blood cells (RBCs), or causing a 
prolonged or subsequent hospitalization (e.g.,  stroke, myocardial infarction) or 
death. To be consistent with International Society of Thrombosis and 
Haemostasis criteria,51 the definition for major bleeding was revised for the 2005, 
2007, and 2009 cohorts as the following: clinically overt bleeding resulting in 
death; located in a critical site (intracranial, intraocular, retroperitoneal, intra-
articular, pericardial, muscular with compartment syndrome); required transfusion 
of ≥2 units of packed RBCs; or resulted in a hemoglobin drop of ≥20 g/L. 
Data collection and management  
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The medical records of all identified patients meeting the diagnostic and 
geographic inclusion criteria were reviewed retrospectively by trained data 
abstractors and validated by clinicians. Standard data abstraction forms were 
developed for the medical record review. Both studies collected information on 
patient’s socio-demographic characteristics, risk factors for VTE, previous and 
concurrent medical conditions, diagnostic methods, therapeutic interventions, 
and outcomes for up to a 3 year period of follow-up. For some major medical 
events that occurred prior to the index event, Cohort-II only included historical 
information for the prior 3 months, compared to the collection of historical data 
over the preceding 6 months for patients included in Cohort-I. In situations where 
patients had been assigned several possible VTE related ICD-9 codes, or had 
received care from multiple hospitals for a single VTE event, potential duplicate 
cases were eliminated in the master database after data collection.  
 
1.10 Approach: methods for aim 1 
To assess 25-year trends (1985-2009) in event rates of VTE, including 
trends in patient characteristics and diagnostic methods, data from patients 
included in Cohort-I and Cohort-II were used. However, cases of upper-extremity 
DVT alone identified in Cohort-II were excluded in this dissertation, since the 
natural history and management of upper-extremity DVT differs from that of 
acute lower-extremity DVT.52-53 In addition, Cohort-I did not include patients with 
upper-extremity DVT alone. 
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 Prior to 1990, in hospital treatment was standard clinical practice for all 
newly diagnosed cases of acute VTE. Outpatient initiation of treatment was 
considered to be unsafe.16 Accordingly, Cohort-I did not include cases treated 
without hospitalization to initiate anticoagulant therapy. 
Event rates  
Data from the United States Census Bureau for individuals residing in the 
WMSA were used as the denominator to calculate various event rates including 
first-time and recurrent VTE. The population estimates per US Census conducted 
in 1985 and 2000 for the city and towns included in the Worcester VTE studies 
are listed in Table 1.3. These crude rates were used to calculate age- and sex-
adjusted rates by the direct adjustment method.54 
Patient socio-demographic characteristics   
Age was calculated as the difference between the date of the index VTE 
event and date of birth. In addition, age was  grouped into several age 
categories,  namely <40 years, 40-49, 50-59, 60-69, 70-79, and 80 years and 
older, in order that my results can be compared to published 25-year trends 
(1966 – 1990) from the Rochester Epidemiology Project.5 Sex and race were 
compared as well.  
Clinical factors  
Hospital length of stay wascalculated as the difference between the dates 
of hospital discharge and admission. Data on medical history were examined, 
including use of hormone therapy (diffreent than comorbid conditions), diabetes, 
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DVT, PE, active malignancy, paralysis of lower extremities, parturition, severe 
burns, multiple trauma, fracture, congestive heart failure, myocardial infarction, 
stroke, chronic obstructive pulmonary disease, and major surgery.  
Signs and symptoms of VTE  
These included leg symptoms of pain, swelling, tenderness, positive 
Holman’s sign, redness, warmth, leg ulcers, or calf circumference, and chest 
symptoms of dyspnea or chest pain, hemoptysis, syncope, elevated jugular 
pressure, pleural friction rub, hypotension, tachycardia, and central cyanosis. A 
Yes/no question related to whether VTE was suspected at the time of hospital 
admission,  emergency room visit, or outpatient visit was collected which was 
used to identify patients who developed VTE in the community setting.  
Objective diagnostic methods  
Objective diagnostic testing methods were reported separately for DVT 
and PE. Tests employed for the diagnosis of VTE were categorized as either 
invasive (venogram and pulmonary angiogram) or non-invasive (impedance 
plethysmography, duplex/ultrasound scan, lung scan, computed tomography 
imaging). 
Analysis methods  
Annual event rates of VTE were reported per 100,000 population. The 
number of first-time VTE served as the numerator for the calculation of event 
rates of first episodes of VTE (incidence rate), while the number of recurrent 
episodes of VTE served as the numerator for the calculation of  event rates of 
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recurrent VTE. The 1985 Census data for the WMSA (n=379,953) were used as 
the denominator for calculation of 1985–1989 annual crude event rates and 2000 
Census data of the WMSA (n=477,598) were used as the denominator for 
calculation of 1999–2009 annual crude event rates.3, 7 These crude rates were 
used to calculate age- and sex-adjusted rates by the direct adjustment method.54 
Since the WMSA population was approximately 90% white during the years 
under study, the age and sex distribution of the 2000 United States white 
(reference) population was used to calculate age- and sex-adjusted rates.5 
Confidence interval (CI) estimates were based on the Poisson distribution. 
Trends in rates during the years under study were assessed by Poisson 
regression. Annual case counts were modeled using the SAS procedure 
GENMOD with a logarithmic link function and a log (population) offset term. A 
main effects model included a term for sex, age group (<40, 40–49, 50–59, 60–
69, 70–79, ≥80 years), and study period. Separate models were constructed for 
episodes of first-time or recurrent VTE, overall, and separated into PE (with or 
without DVT) and DVT-alone. 
Patient characteristics and diagnostic tests were reported as frequencies 
and percentages for categorical variables and as means (standard deviations) or 
medians (interquartile ranges) for continuous variables. The Cochran-Armitage 
tests and linear regression models were used to test for linear trends over time 
among categorical variables and continuous variables, respectively. 
Comparisons between the 2009 cohort with the 1985/86 cohort were performed 
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using the chi-square or Fisher’s exact test for categorical variables and the 
Wilcoxon rank-sum test for continuous variables.  
All analyses were performed using SAS 9.2 (SAS Institute Inc., Cary, NC) 
and statistical significance level was specified as α=.05 (two-sided). 
 
1.11 Approach: methods for aim 2 
The primary objectives of this aim are to assess recent decade long trends 
(1999–2009) in the clinical management and long-term outcomes among patients 
with an initial episode of VTE that developed in the community setting. The 
working definitions of a first-time VTE, and VTE occurring in the community 
setting, were the same as the definition used in Aim 1.  
Clinical management practices included prior VTE prophylaxis status 
among patients who underwent prior surgery or a non-surgical-related 
hospitalization. In the early 1990s, with the introduction of subcutaneous 
LMWHs, which did not require dose adjustment (LMWHs replaced UFH), the 
outpatient treatment of VTE was made possible.38-42 Therefore, trends in the 
adoption of new treatment methods were examined, including initial treatment 
setting (in-hospital or outpatient clinic) and type of therapy (UFH, warfarin, or 
LMWH).   
 Decade long trends in adverse event rates of all-cause mortality, major 
bleeding episodes, and recurrent VTE within 3 years of the index event were 
assessed.  
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Analysis plan:   
Categorical variables were reported as frequencies and percentages and 
continuous variables as means, standard deviations, medians, and interquartile 
ranges. Cochran-Armitage tests for binomial variables, Mantel-Haenzel tests for 
multinomial variables, and linear regression models for continuous variables 
were used to examine trends during the years under study. Differences in the 
characteristics, management, and outcomes of patients diagnosed with VTE in 
2009 versus those in 1999 were examined using the chi-square or Fisher’s exact 
test for categorical variables and the Wilcoxon rank-sum test for continuous 
variables. 
To further evaluate whether study year at the time of VTE presentation 
was associated with our pre-specified outcomes over our  3-year follow-up, 
including occurrence of recurrent VTE, major bleeding, and all-cause mortality, 
Kaplan-Meier curves with log-rank tests and multivariable Cox proportional 
hazard regressions were constructed. Multivariable Cox proportional hazard 
regressions controlled for age, sex, index diagnosis of VTE (PE with/without (±) 
DVT vs. DVT alone), and medical history within 3 months before the index event. 
Patients who experienced a major bleeding episode before the development of a 
recurrent VTE over the course of follow-up were excluded from the recurrent VTE 
regression model; patients with recurrent VTE prior to major bleeding during 
follow-up were excluded from the major bleeding regression model. All follow-up 
data were censored at the last contact (3 years) for mortality, and death or the 
22 
 
last contact (3 years) for major bleeding and recurrent VTE following the index 
event.   
All analyses  were performed using SAS 9.2 (SAS Institute Inc., Cary, NC) 
and statistical significance level was specified as α=.05 (2-sided). 
 
1.11 Approach: methods for aim 3 
Due to the availability of data on long-term follow-up, only data from 
Cohort-II were used for this analysis. In addition, only identified first episodes of 
VTE were included. Risk factors associated with recurrence after index event 
were identified. Evidence-based RAMs were developed to predict VTE 
recurrence during short- (3 months) and long-term (3 years) follow-up after the 
index event. Risk score calculator(s) based on the 3-month prognostic model 
were created.    
Outcome  
Recurrent VTE following an index event (defined in section 1.9) was the 
primary outcome for this analysis. The risk period was divided into short-term (3 
months post index event) and long-term (3 years post index event).   
Potential risk factors  
The candidate predictors included patient demographics, medical history, 
recent clinically recognized VTE risk factors, and initial treatment (including initial 
and chronic outpatient anticoagulant therapy). 
Analysis methods  
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The distributions of patient characteristics were assessed during the index 
encounter (potential risk factors) and were described using means, standard 
deviations, medians and inter-quartile ranges for continuous variables; these 
data were presented as percentages for categorical variables. Hazard ratios 
(HRs) and 95% confidence intervals (CIs) generated by the unadjusted Cox 
proportional hazard regression were used to illustrate the relationship of potential 
prognostic factors to time to recurrent episodes of VTE. 
Cumulative incidence rate (CIR) of VTE recurrence within 3 years after the 
patient’s index event were estimated using the Kaplan-Meier methods. Data were 
censored at death or last contact (3 years) following the index event.  
Prognostic models for predicting risk of VTE recurrence after the index 
event were developed using these methods: the full model included all potential 
risk factors identified by unadjusted Cox proportional hazard regressions with 
p≤0.1; multivariable Cox regression backwards selection procedures were used 
to select final independent predictors (p<0.05). Proportional hazards assumptions 
were assessed by a test of the interaction between log (time metric) and each 
predictor. The linearity of age at index encounter were assessed by the fractional 
polynomial technique.55 Possible 2-way interactions among the final risk 
predictors were assessed. Model discrimination was  assessed using the Harrell 
macro for Cox regression (the c-index),56 while goodness-of-fit (calibration) was  
assessed by the May-Hosmer methods.57  
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The final prognostic model for predicting 3-month VTE recurrence was 
used to develop the 3-month risk score calculator based on methods commonly 
used in published studies.58-62 The risk score was calculated as follows: the factor 
with the smallest logarithmic HR (natural log of HR) was assigned 1 point, with 
other factor scores based on the size of their estimates relative to the smallest 
logarithmic HR; Individual predictor scores were summed to give a total risk 
score (on a 0-100 scale) for each patient. The accuracy of calibration was 
demonstrated by comparing model-predicted to observed VTE risk (using the 
Kaplan-Meier method) over the full range of VTE risk scores.57 
Since use of the maximum sample size leads to the best unbiased 
estimates, it is least likely to cause a type II error. In addition, no study can 
effectively validate itself: “a true evaluation of generalisability (also called 
transportability) requires evaluation on data from elsewhere”.63 Therefore, 
internal validation of the model results by using a split sample technique was not 
attempted. 
 All analyses were performed using SAS 9.2 (SAS Institute Inc., Cary, NC) 
and statistical significance level was specified as α=0.05 (two sided). 
 
1.12 Sample size and power estimates 
All calculations were performed using the PASS software version 11 with a two-
sided α=0.05. 
Sample size estimates  
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Previous publications from the Worcester VTE studies indicated that there 
were 615 cases in the 1985/86 group, 618 cases in the 1988/89 cohort and 
approximately 1,800 cases in the1999/01/03 cohorts.3, 7, 27 I anticipate that at 
least an additional 1,800 additional cases will be included in the 2005/07/09 
patient cohorts. Previous publications from Cohort-II indicated that 14% of VTE 
cases were upper-extremity DVT,52 and approximately 12% of recurrent VTE 
cases presented as the index event.18, 27 After excluding either upper-extremity 
DVT in Cohort-II or recurrent VTE, the estimated sample sizes for each aim are 
listed in Table 1.4.  
For Aim-3, the cumulative VTE recurrence rate within 3-years since the 
index event is approximately 17% based on previously published data.18 
Therefore, the estimated total number of recurrent VTE events accumulated 
within 3-years after the index event will be approximately 450.  
Based on previous publications, the expected survival or mortality rates 
are approximately 10% within 30 days, and 30% within 3-years, following the 
index event.18 
Power estimates for analysis of patient characteristics and clinical management 
practices  
The estimated sample size for each aim suggests that the sample size is 
more than adequate to estimate differences between patient subsets for a variety 
of endpoints (e.g., individual diagnostic and treatment modalities). Table 1.5 
provides the 95% confidence interval estimates for proportions in the expected 
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range of sample sizes in the proposed aims. The widths of these confidence 
intervals suggest that considerable precision is possible.  
Power estimates for hypothesis tests  
For all five hypothesis tests of study aims 1 and 2, chi-square tests were  
used to compare two independent binomial proportions, P1 and P2. The null 
hypothesis is that P1=P2. The alternative hypothesis is P1≠P2. Based on the 
projected sample size, a minimum of 400 patients would be available in each 
group. Table 1.6 provides estimates of the minimum detectable difference in 
proportions for power of 80% and α=0.05 for the expected range of proportions 
and available sample sizes.  
Power estimates for Cox proportional hazards model  
The sample estimates indicate that at least 2,700 VTE cases are available 
for aim-3. Due to the methods employed to capture follow-up events in Cohort-II, 
the rate of missing data should be very low. Inasmuch, it is likely that the number 
of individuals included in this analysis will be more than 2,700 with an expected 
17% recurrence rate. The estimated power for a range of hazard ratios (HR) is 
provided in Table 1.7, which suggests that this analysis will be adequately 
powered to detect an HR of 1.3 or larger. 
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1.14 Tables 
Table 1.1: ICD-9 Codes Used to screen and Identify VTE Cases 
 
ICD-9 Code Description Cohort I Cohort II 
Deep venous thrombosis 
451.1 Of deep vessels of lower extremities X X 
451.11 Femoral vein phlebitis X X 
451.19 Deep phlebitis-leg nec  X X 
451.81 Iliac  thrombophlebitis X X 
451.83 Of deep veins of upper extremities  X 
451.89 Thrombophlebitis nec  X 
451.9 Thrombophlebitis nos  X 
453.1 Thrombophlebitis migrans  X 
453.2 Oth inf vena cava thromb X X 
453.8 Acute venous embolism and thrombosis of other 
specified veins 
X X 
453.9 Venous thrombosis nos X X 
671.3 (0,1,3) Deep phlebothrombosis antepartum X X 
671.4 (0,2,4) Deep phlebothrombosis postpartum X X 
671.9 (0 to 4) Unspecified venous complications X X 
673.2 (0 to 4) Obstetrical blood-clot embolism  X 
673.24 Obstetrical blood-clot embolism  X 
996.73 Other complications; due to renal dialysis device, 
implant, graft 
 X 
996.74 Other complications; due to other vascular 
device, implant, graft 
 X 
997.2 Peripheral vascular complications, Phlebitis or 
thrombophlebitis during or resulting from a 
procedure, Excludes:, the listed conditions due 
to:, implant or catheter device 
X X 
999.2 Complication of medical care; other vascular 
complications, Thromboembolism following 
infusion, perfusion, or transfusion, 
Thrombophlebitis following infusion, perfusion, or 
transfusion 
X  
Pulmonary embolism 
415.1 Pulmonary embolism and infarction X X 
415.11 Iatrogen pulm emb/infarc  X 
415.19 Pulm embol/infarct nec  X 
639.6 Embolism X  
996.7 Other complications of internal (biological) 
(synthetic) prosthetic device, implant, and graft 
X  
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Table 1.2: Criteria for classification of VTE events 
 
Classification Description 
Deep vein thrombosis 
Definite if confirmed by venography, compression/Duplex ultrasound, CT scan, 
MRI scan, or at autopsy 
Probable if the above tests were not performed, or were indeterminate, but 
impedance plethysomography, radionuclide venography, or radiolabelled 
fibrinogen scan test results were reported as positive. 
Possible if all of these confirmatory tests were not performed, or were 
indeterminate, and 2 of the following criteria were satisfied – medical 
record indicates that the physician made a diagnosis of DVT, signs and/or 
symptoms of DVT were documented, and the patient underwent therapy 
with anticoagulants, or an IVC filter was placed. 
Pulmonary embolism 
Definite if confirmed by pulmonary angiography, spiral CT scan, MRI scan, or 
pathology. 
Probable if the above tests were not performed, or were indeterminate, but 
ventilation-perfusion scan findings were of high probability. 
Possible if all of the above confirmatory tests were not performed, or were 
indeterminate, and 2 of the following criteria were satisfied – medical 
record indicates that the physician made a diagnosis of PE, signs and/or 
symptoms of PE were documented, and the patient underwent therapy 
with anticoagulants, or an IVC filter was placed. 
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Table 1.3: US Census Estimates for Towns included in Worcester VTE Study 
 
Towns ZIP CODE  Y1985   Y2000  
Auburn 01501          14,468        15,901  
Barre* 01005  -           5,113  
Berlin 01503              2,217           2,380  
Boylston 01505              3,450           4,008  
Brookfield 01506              2,556           3,051  
Charlton 01507              7,490         11,263  
Clinton* 01510                   -           13,435  
Douglas* 01516                   -             7,045  
Dudley* 01570-01571                   -           10,036  
East Brookfield 01515              1,915           2,097  
Grafton 01529            11,867         14,894  
Holden 01520            13,555         15,621  
Leicester 01524              9,567         10,471  
Millbury 01597            11,672         12,784  
North Brookfield 01535              4,142           4,683  
Northborough 01532            10,766         14,013  
Northbridge 01534            12,285         13,182  
Oxford 01540            11,895         13,352  
Paxton 01612              8,690           4,386  
Princeton* 01541                   -             3,353  
Rutland* 01543                   -             6,353  
Shrewsbury 01545            22,653         31,640  
Spencer  01562            11,289         11,691  
Sterling 01564              5,832           7,257  
Sutton 01590              6,345           8,250  
Upton 01568              4,164           5,642  
Uxbridge 01569              8,633         11,156  
Webster 01570            14,824         16,415  
West Boylston 01583              6,057           7,481  
Westborough 01581            13,132         17,997  
Worcester 01601-01610          160,489        172,648  
Total    379,953  477,598 
*Towns were not considered as Worcester Statistical Metropolitan Area in 1985 
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Table 1.4: Sample Size Estimates 
 
Cohort 85/86 88/89 99/01/03 05/07/09 Total 
Total enrolled 615 618 1800 1800 4833 
Aim-1 sample* 615 618 1548 1548 4329 
Aim-2 sample§ 0 0 1362 1362 2724 
Aim-3 sample§ 0 0 1362 1362 2724 
*excluding upper-extremity DVT;  
§excluding recurrent VTE as index event. 
 
Table 1.5: Expected Widths of 95% confidence Intervals for One Proportion 
 
Sample size P=0.5 P=0.4 P=0.3 P=0.2 P=0.1 
100 0.098 0.096 0.090 0.078 0.059 
500 0.044 0.043 0.040 0.035 0.026 
1000 0.031 0.030 0.028 0.025 0.019 
2000 0.022 0.021 0.020 0.018 0.013 
3000 0.018 0.018 0.016 0.014 0.011 
4000 0.015 0.015 0.014 0.012 0.009 
5000 0.014 0.014 0.013 0.011 0.008 
Width=1.96*SQRT((p*(1-p))/n) 
 
 
Table 1.6: Minimum Detectable Differences for the Stated N and base Proportion (P1) 
 
N per 
group 
P1=0.5 P1=0.4 
or 0.6 
P1=0.3 
or 0.7 
P1=0.2 
or 0.8 
P1=0.1 
or 0.9 
400 0.0981 0.0981 0.0938 0.0845 0.0671 
500 0.0879 0.0800 0.0837 0.0751 0.0593 
600 0.0804 0.0804 0.0763 0.0683 0.0537 
800 0.0697 0.0697 0.0659 0.0587 0.0459 
1000 0.0624 0.0624 0.0588 0.0523 0.0407 
2000 0.0442 0.0442 0.0413 0.0366 0.0281 
α=0.05 and β=0.20 
 
 
Table 1.7: Cox Regression Power Analysis 
 
Power Regression  
Coefficient 
Hazard  
Ratio 
90% 0.3041 1.355 
80% 0.2629 1.301 
70% 0.2331 1.262 
α=0.05; Sample size = 2700; Event Rate= 17% 
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Chapter II. Secular Trends in Occurrence of Acute Venous 
Thromboembolism: The Worcester VTE Study (1985 to 2009) 
 
2.1 Abstract 
Background: The clinical epidemiology of venous thromboembolism (VTE) has 
changed recently due to advances in identification, prophylaxis, and treatment. 
We described secular trends in the occurrence of VTE among residents of the 
Worcester, Massachusetts, metropolitan statistical area (WMSA).  
Methods: Population-based methods were used to monitor trends in event rates 
of first-time or recurrent episodes of pulmonary embolism (PE) and/or deep vein 
thrombosis (DVT) in 5025 WMSA residents diagnosed with acute PE and/or 
lower-extremity DVT during 9 annual periods between 1985 and 2009. Medical 
records were reviewed by abstractors and validated by clinicians.  
Results: Age- and sex-adjusted annual event rates for first-time VTE increased 
from 73 (95% CI 64–82) per 100,000 in 1985/1986 to 133 (122–143) in 2009, 
due mostly to an increase in PE. The rate of recurrent VTE decreased from 39 
(32–45) in 1985/1986 to 19 (15–23) in 2003, and then increased to 35 (29–40) in 
2009. There was an increasing trend in the use of non-invasive diagnostic 
testing, with about half of tests being invasive in 1985/1986 and almost all being 
non-invasive by 2009.  
Conclusions: Despite advances in identification, prophylaxis, and treatment 
between 1985 and 2009, the annual event rates of VTE have increased and 
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remain high. While these increases may be partially due to increased sensitivity 
of diagnostic methods, especially for PE, it may also imply that current prevention 
and treatment strategies are less than optimal. 
 
2.2 Introduction 
Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and 
pulmonary embolism (PE), is associated with increased long-term morbidity, 
functional disability, and all-cause mortality.1 Over three decades ago, VTE was 
estimated to be the third most common acute cardiovascular event after the 
acute coronary syndromes and ischemic stroke.2 Recent data on the clinical 
epidemiology of VTE are, however, limited.6 
Considerable variation exists in estimates of the annual incidence rates of 
VTE, derived from population-based studies and hospital discharge or health-
insurance claims databases.6 Major advances have occurred in identifying 
patients at increased risk for VTE, in thromboprophylaxis, and in diagnostic 
methods and treatments.6, 8-13 Growing awareness of VTE as an important public-
health problem became the impetus for evidence-based guidelines for 
appropriate VTE prevention and treatment, which have been revised over time.43, 
64 These advances have likely influenced the reported frequency of VTE.  
Using data from the Worcester VTE study (1985 to 2009), we describe 25-
year trends in event rates, patient characteristics, and use of various diagnostic 
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approaches among residents of the Worcester, Massachusetts, metropolitan 
statistical area (WMSA) diagnosed with clinically recognized acute VTE. 
 
2.3 Methods 
The Worcester VTE study employed population-based surveillance methods to 
monitor trends in event rates of VTE (first-time or recurrent episodes of PE 
and/or DVT), including management strategies, case-fatality rates, and 
recurrences after the index event among WMSA residents.3, 7, 27, 44 Reflecting the 
evolution of the standard of care for the treatment of acute VTE, Cohort-I 
included all hospital inpatients discharged with a primary/secondary diagnosis of 
VTE during two 18-month periods, July 1985 to December 1986, and July 1988 
to December 1989. Cohort-II included hospitalized patients and outpatients 
diagnosed with VTE based on outpatient, emergency department, radiology 
department, or diagnostic laboratory encounter during 1999, 2001, 2003, 2005, 
2007, and 2009. Medical records were reviewed by trained abstractors and 
validated by clinicians.  
This study was approved by the institutional review committee at 
participating hospitals. 
VTE Definition  
Both cohorts used International Classification of Disease, 9th revision, 
codes to identify eligible acute cases of PE and/or DVT (Table 1.1). There were 
slight differences in our study populations due to the refinement of these codes 
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over the years. In addition, Cohort-II included patients diagnosed with upper-
extremity DVT alone. These were excluded in the present analyses due to 
important differences in the natural history of upper-extremity and lower-extremity 
DVT.52-53   
Patients were classified as either ‘first-time’ if the index event was a first-
time episode, or as ‘recurrent’ at the time of the index visit if the patient had a 
prior episode of VTE noted in their medical records.  
Data Analysis 
Annual event rates of VTE are reported per 100,000 population. The 
number of first-time VTE episodes served as the numerator for calculation of 
event rates of first-time VTE (incidence rate), while the number of cases of 
recurrent VTE served as the numerator for calculation of the event rates of 
recurrent VTE. The 1985 United States (US) Census data of the WMSA 
(n=379,953) were used as the denominator for calculation of 1985–1989 annual 
crude event rates and 2000 Census data of the WMSA (n=477,598) were used 
as the denominator for the calculation of 1999–2009 annual crude event rates.3, 7 
These crude rates were used to calculate age- and sex-adjusted rates by the 
direct adjustment method.54        
 Since the WMSA population was approximately 90% white during the 
years under study, the age and sex distribution of the 2000 United States white 
(reference) population was used to calculate age- and sex-adjusted rates.5 
Confidence interval (CI) estimates were based on the Poisson distribution. 
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Trends in rates during the years under study were assessed by Poisson 
regression. Annual case counts were modeled using the SAS procedure 
GENMOD with a logarithmic link function and a log (population) offset term. A 
main effects model included a term for sex, age group (<40, 40–49, 50–59, 60–
69, 70–79, ≥80 years), and study period. Separate models were constructed for 
episodes of first-time or recurrent VTE, overall, and separated into PE with or 
without DVT (±DVT) and DVT alone. 
Patient characteristics and diagnostic tests are reported as frequencies 
and percentages for categorical variables, and as means (standard deviations) or 
medians (interquartile ranges) for continuous variables. The Cochran-Armitage 
tests and linear regression models were used to test for linear trends over time 
among categorical variables and continuous variables, respectively. Comparison 
of the 2009 cohort with the 1985/86 cohort was performed using the chi-square 
or Fisher’s exact test for categorical variables and the Wilcoxon rank-sum test for 
continuous variables.  
All analyses were performed using SAS 9.2 (SAS Institute Inc., Cary, NC) and 
statistical significance level was pre-specified as α=.05 (two-sided). 
 
2.4 Results 
During the study period (1985–2009), 5487 WMSA residents were 
diagnosed with acute PE and/or DVT (1235 from Cohort-I, 4252 from Cohort-II). 
After excluding 462 (10.9%) patients diagnosed with upper-extremity DVT alone 
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in Cohort-II, 5025 patients with a diagnosis of acute PE±DVT or lower-extremity 
DVT alone were examined in the present analyses. This included 3887 (77.4%) 
first-time VTE and 1138 (22.6%) episodes of recurrent VTE. Increases in the 
proportion of first-time episodes of VTE were observed over time from 
approximately two-thirds in the initial cohort to nearly 80% in the 2009 cohort 
(trend P<.001, Table 2.1).  
Patient Characteristics at Index Visit 
Among the 5025 patients diagnosed with VTE, 46% were men, 95% were 
white, and their  mean age was 64.6 (±17.8) years. Patients diagnosed with first-
time VTE tended to be younger and include an increasing proportion of ethnic 
minorities over the study period, but no changes were apparent in the recurrent 
VTE group (Table 2.1). Increases in body mass index and diabetes, whereas  
declines were observed  in the frequency of prior congestive heart failure, stroke, 
and malignancy, in patients with first-time and recurrent VTE. Among patients 
with first-time VTE, there was a decrease in the proportion of patients who had 
recent surgery, trauma, or major fracture during the years under study.  
The proportion of patients with community-accquired VTE remained 
approximately 80% over time among patients presenting with first-time VTE, but 
decreased from approximately 91% to 78% among those diagnosed with 
recurrent VTE at the time of their index visit (P for trend =.001). Overall, the 
proportion of patients admitted to the hospital for treatment of VTE, or who 
developed index VTE during hospitalization for another diagnosis, decreased 
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from 100% to approximately 70% during the years under study. Among 
hospitalized patients, the mean length of stay during the index hospitalization 
decreased markedly over time in all patient groups.  
Annual Event Rates  
Among residents of the WMSA during the period 1985 to 2009, the overall 
age- and sex-adjusted annual event rate (per 100,000) was 108 (95% CI, 98 to 
118) for first-time VTE and 34 (95% CI, 28 to 40) for recurrent VTE. Further 
stratifying VTE into PE±DVT and DVT alone, the overall age- and sex-adjusted 
annual event rate (per 100,000) was 41 (95% CI, 35 to 47) for first-time PE±DVT, 
66 (95% CI, 59 to 74) for first-time DVT alone, 9.6 (95% CI, 6.6–12.6) for 
recurrent PE±DVT, and 25 (95% CI, 20 to 29) for recurrent DVT alone.  
There were increases over time in the age- and sex-adjusted annual event 
rates of first-time VTE from 73/100,000 to 133/100,000 (P<.001, Figure 2.1A). 
Poisson regression indicated an approximate 40% increase in first-time VTE from 
1985 to 2001, which remained essentially unchanged in the early 2000s, followed 
by an additional 50% increase by 2009 (Table 2.2). Although the pattern of first-
time VTE observed in WMSA between the late 1980s and early 2000s was 
similar in PE±DVT and DVT alone groups, the increasing trend in the late 2000s 
predominantly reflected an increase in the age- and sex-adjusted annual event 
rate of first-time PE±DVT, which increased from 35/100,000 in 2003 to 
65/100,000 in 2009 (P<.001, Figure 2.1A).  
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Trends in the age- and sex-adjusted annual event rates of recurrent VTE 
were U-shaped (Figure 2.1B). Poisson regression indicated an approximate 40% 
decrease in the event rates of recurrent VTE between the mid-1980s and 1999, 
which remained relatively unchanged in the early 2000s, then increased in the 
late 2000s (Table 2.2). Similar trends were found for those with PE±DVT and 
DVT alone (Figure 2.1B).     
Crude and adjusted annual event rates for each study period, as well as 
by VTE type, are shown in Table 2. These rates increased markedly with age 
regardless of VTE type, sex, or study period (Table 2.2S). 
Objective Diagnostic Tests  
The proportion of patients undergoing at least one objective (either 
invasive or non-invasive) diagnostic test rose, with rates of non-invasive testing 
increasing from 60–70% in 1985/86 to nearly 100% in 2009, while the rates of 
invasive testing plunged from over 50% to near zero (Table 2.3). In particular, 
there was a marked increase in the use of computed tomography and magnetic 
resonance imaging scans in the late 2000s (Table 2.3). 
 
2.5 Discussion 
The Worcester VTE study provides a unique opportunity to examine 25-
year trends in the magnitude, characteristics, and diagnostic workup for VTE 
from the perspective of a well-characterized population. The disease burden from 
VTE in this central Massachusetts population remains high, with a trend towards 
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increasing annual event rates as well as substantial changes in patient 
characteristics and methods used to diagnose VTE between 1985 and 2009.  
Disease Burden  
The age- and sex-adjusted annual event rates of clinically recognized 
acute first-time and recurrent VTE was 142/100,000 during the entire study 
period, increasing from 112/100,000 in 1985/86 to 168/100,000 in 2009. It is 
higher than the incidence of the leading two cancers (126/100,000 for prostate 
cancer and 124/100,000 for breast cancer) and >15 times higher than the 
incidence rate of HIV (8.3/100,000) in white Americans.65 The age- and sex-
adjusted annual event rate of clinically recognized acute PE±DVT was 
78/100,000 in 2009, nearly equivalent to the annual incidence of ischemic stroke 
(88/100,000) in white individuals reported by the American Heart Association 
during that period.54 
With increased long-term morbidity and functional disability, and high rates 
of recurrence and mortality among VTE patients,1 this disorder remains a major 
national health problem.  
Trends in Occurrence 
Between 1985 and 2009, the annual event rates of first-time VTE nearly 
doubled, and first-time PE±DVT nearly tripled, with inconsistent patterns noted 
among patients with recurrent VTE.  
Our study is the first population-based surveillance project of VTE to 
provide data about trends in annual event rates of first-time and recurrent VTE 
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between 1985 and 2009. Data from the Rochester Epidemiology Project (REP), 
the study with the most similar design to ours, indicated a 23% increase in the 
age- and sex-adjusted annual event rate of first-time VTE from 96/100,000 in 
1986–1990 to 118/100,000 in 1991 to 1997.5, 66 These results are similar to the 
30% increase in the age- and sex-adjusted annual event rate of first-time VTE 
observed in our study between 1985 and 1999.      
  In the US Nationwide Inpatient Sample,  the number of patients with first-
time and recurrent PE±DVT discharged from US acute care hospitals 
approximately doubled between 1998 and 2005,67 consistent with our findings. A 
retrospective study based on estimates derived from commercial insurance and 
Medicare databases of insured US residents observed a 33% increase in annual 
event rates of first-time and recurrent VTE between 2002 and 2006.68 This 
increase was larger than the approximate 20% increase in the age- and sex-
adjusted annual event rates of first-time and recurrent VTE observed in the 
present study (from 131/100,000 in 2001 to 154/100,000 in 2007). These results, 
based on commercial insurance and Medicare databases, may be limited due to 
their reliance on administrative databases without actual chart review and 
independent diagnostic validation.  
Both the Rochester Epidemiology Project and our study indicated that the 
frequency of VTE increased markedly with advancing age regardless of study 
year, VTE type, or sex. Given the aging of the United States population,69 the 
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projected disease burden of VTE is expected to more than double between 2006 
and 2050.68 
Possible Contributory Factors to Observed Trends  
Observed increases in the frequency of VTE during the study period are 
likely to be multifactorial. First, the use of one or more non-invasive diagnostic 
methods for the detection of VTE increased from approximately two-thirds of 
patients in 1985 to nearly all in 2009. In particular, the introduction of computed 
tomography pulmonary angiography (CTPA) closely parallels the observed 
increases in the annual event rate of first-time and recurrent PE±DVT observed 
in our study. The proportion of PE±DVT patients who underwent a CTPA test 
increased from approximately 25% in 1999 to 85% in 2009. During this period, 
the annual event rate of first-time and recurrent PE±DVT more than doubled.  
A time-trend analysis using the Nationwide Inpatient Sample and Multiple 
Cause-of-Death databases demonstrated that the introduction of CTPA was 
associated with changes consistent with a rising frequency of PE in the US 70. 
Clearly,  we are detecting more cases of VTE during recent years than were 
detected (or were detectable) in the decades before the introduction of newer 
technology. A more difficult question to address is how much of this increase 
represents small, clinically insignificant PEs? Following the introduction of high-
resolution multiple-detector CTPA, systematic reviews and meta-analyses have 
suggested an increase in the diagnosis of subsegmental PEs of unclear clinical 
significance through the use of these newer testing modalities.71 Because most 
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of these subsegmental PEs are treated, their importance remains a key 
healthcare and resource issues. Further study of this issue is warranted. 
With expanded access to higher resolution diagnostic imaging, a growing 
awareness of VTE as an important public-health problem may have led clinicians 
to refer additional patients for evaluation.72 Our findings indicate that the 
proportion of patients who received any form of objective diagnostic testing has 
increased over time.  
In addition to changes in the diagnosis of VTE, the increases in annual 
event rates of VTE observed in WMSA residents could also be related to 
changes in population characteristics over time. As the US population ages and 
becomes less active and more obese,65, 69 it may lead to further increases in risk 
of developing VTE.  
Although the development and implementation of evidence-based practice 
guidelines for VTE prevention and treatment may have reduced the annual event 
rate of VTE among ‘high-risk’ patients, including those with a recent history of a 
surgical procedure, pregnancy, trauma, fracture, and hospitalization,48 this would 
not be expected to impact patients without obvious recent provocations who 
would be less likely to have received enhanced VTE prophylaxis compared with 
high-risk patients.  
Our findings demonstrate that the proportion of patients with community-
accquired first-time VTE has remained relatively constant, at approximately 80%, 
during the 25-year period under study. A prior publication from our study 
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suggests that approximately 40% of patients with community-acquired VTE had a 
hospitalization or surgery in the 3 months before their index visit.45 Further work 
identifying and providing prophylaxis to high-risk patients being discharged from 
hospital is needed. With respect to the remaining 60% (with unprovoked VTE), 
research aimed at better understanding such patients by risk and identifying 
possible “minor” triggers for a VTE event may provide additional opportunities for 
prophylaxis.     
Interestingly, although the annual event rate of recurrent VTE remained 
relatively unchanged between 1985 and 2009, the trend was U-shaped. The 
decreasing trend observed between the late 1980s and 1999 could be due to 
improved treatment strategies.32, 38-42, 73 However, given increases in the annual 
event rates of first-time VTE and high recurrence of this thromboembolic 
disorder,1, 11  it was not surprising that the annual event rates of recurrent VTE 
also increased in the WMSA during the late 2000s. 
Study Strengths and Limitations 
The Worcester VTE study employed rigorous population-based 
surveillance methods to describe the clinical epidemiology of acute VTE in the 
WMSA. Although we conducted broad screening for cases of VTE using multiple 
databases, validated each potential case of VTE, and performed regular chart 
audits, it is possible that this study may have missed some cases. Owing to low 
autopsy rates in the WMSA, and the limited validity of death-certificate data, only 
clinically recognized cases of acute VTE were described and some cases of fatal 
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PE could be missed. Further, regional differences may exist in the diagnostic 
workup of patients presenting with signs and symptoms of VTE. Since the WMSA 
is predominantly a white population, additional population-based studies in 
minority and economically disadvantaged populations are needed.  
 
2.6 Conclusions 
Despite advances in identification, prophylaxis, and treatment between 
1985 and 2009, the annual event rate of VTE has increased and remains high. 
While these increases may be partially due to increased sensitivity of diagnostic 
methods, especially for PE, it may also imply that current prevention and 
treatment strategies are less than optimal.  
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2.7 Tables and figures 
Table 2.1 Characteristics of patients with venous thromboembolism in the Worcester venous thromboembolism study (1985–
2009)  
 
 Study year P value 
 1985/1986 
(n=617) 
1988/1989 
(n=618) 
1999 
(n=539) 
2001 
(n=597) 
2003 
(n=554) 
2005 
(n=608) 
2007 
(n=698) 
2009 
(n=794) 
Trend 
test 
1985/86 
vs. 2009 
First-time venous thromboembolism at index 
visit, n (% of total venous thromboembolism) 
405 (65.6) 442 (71.5) 435 (80.7) 482 (82.4) 466 (84.1) 482 (79.3) 542 (77.7) 633 (79.7) <.001 <.001 
  Demographic characteristics           
    Age (years)         .001 .04 
      Mean (standard deviation) 65.9 (17.2)  66.4 (17.4) 66.4 (17.7) 65.8 (17.3) 63.0 (17.9) 62.7 (18.9) 65.0 (18.1) 63.7 (17.8)   
      Median (interquartile range) 69 (60–78) 70 (60–78) 72 (54–80) 69 (54–81) 65 (50–78) 65 (48–79) 68 (52–80) 65 (50–80)   
    Men (%) 48.6 45.5 43.4 41.9 46.8 41.3 47.6 44.6 .34 .75 
    White (%) 97.5 98.2 95.4 93.5 93.6 94.8 95.7 92.5 <.001 .001 
  Recent* medical characteristics (%)           
    Body mass index class           
      <25 kg/m2 42.1 44.2 35.3 32.9 26.0 36.5 28.9 26.9 <.001 <.001 
      25–30 kg/m2  35.1 28.8 27.4 31.4 33.3 28.4 35.2 29.5 .80 .11 
      >30 kg/m2 22.8 27.1 37.3 35.6 4.7 35.1 35.9 43.6 <.001 <.001 
    Congestive heart failure 20.2 11.5 13.1 14.9 11.2 10.0 9.2 7.4 <.001 <.001 
    Myocardial infarction 4.9 3.4 5.1 7.3 6.4 4.1 3.0 2.5 .25 .04 
    Stroke 4.2 6.6 6.4 7.1 5.6 2.7 2.2 2.2 .001 .07 
    Chronic obstructive pulmonary disease 23.2 15.8 17.0 21.4 16.7 21.8 24.7 23.7 .04 .86 
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 Study year P value 
 1985/1986 
(n=617) 
1988/1989 
(n=618) 
1999 
(n=539) 
2001 
(n=597) 
2003 
(n=554) 
2005 
(n=608) 
2007 
(n=698) 
2009 
(n=794) 
Trend 
test 
1985/86 
vs. 2009 
    Diabetes 14.3 16.5 17.0 22.4 18.0 17.2 23.4 18.8 .005 .06 
    Malignancy 30.4 23.3 19.3 19.9 12.7 15.6 16.8 19.0 <.001 <.001 
    Trauma/fracture  12.8 13.8 17.7 21.0 13.5 9.8 8.9 9.5 .006 .09 
    Hormone replacement therapy/oral 
contraceptives† 
4.3 4.6 21.1 21.4 14.9 10.6 7.4 10.9 .008 .01 
    Post partum†  3.8 1.7 2.4 1.1 1.2 2.5 1.1 1.4 .08 .07 
    Any surgery, including index admission 34.6 30.5 29.2 30.5 25.8 28.2 23.2 22.7 <.001 <.001 
  Venous thromboembolism characteristics (%)           
    Type of venous thromboembolism event           
      Pulmonary embolism alone 24.2 22.2 15.9 20.5 18.9 28.4 29.9 28.8 <.001 .11 
      Pulmonary embolism and deep vein 
thrombosis 
8.2 6.6 15.6 14.7 15.2 18.9 19.6 19.7  <.001 <.001 
Lower-extremity deep vein thrombosis alone 67.7 71.3 68.5 64.7 65.9 52.7 50.5 51.5 <.001 <.001 
    Community acquired 78.0 80.1 73.6 75.1 75.8 78.8 79.5 77.1 .68 .73 
  Hospital encounter,            
    Admitted to hospital§ (%) 100 100 77.7 77.2 70.8 74.3 73.1 71.1 <.001 <.001 
    If admitted, length of stay, days         <.001 <.001 
      Mean (standard deviation) 15.3 (24.1) 15.1 (15.5) 9.0 (10.0) 10.1 (11.5) 9.6 (10.8) 8.5 (11.0) 7.2 (8.6) 6.9 (8.0)   
      Median (interquartile range) 10 (8–19) 10 (7–16) 6 (4–9) 6 (4–10) 6 (4–10) 5 (3–9) 5 (3–8) 5 (3–8)   
Recurrent venous thromboembolism at index 212 (34.4) 176 (28.5) 104 (19.3) 115 (19.3) 88 (15.9) 126 (20.7) 156 (22.4) 161 (20.3) <.001 <.001 
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 Study year P value 
 1985/1986 
(n=617) 
1988/1989 
(n=618) 
1999 
(n=539) 
2001 
(n=597) 
2003 
(n=554) 
2005 
(n=608) 
2007 
(n=698) 
2009 
(n=794) 
Trend 
test 
1985/86 
vs. 2009 
visit, n (% of total venous thromboembolism) 
  Patient characteristics           
    Age (years)         .10 .17 
      Mean (standard deviation) 62.6 (17.3) 61.1 (19.0) 64.1 (16.6) 64.7 (17.2) 65.4 (17.7) 63.8 (18.0) 66.9 (15.5) 64.9 (16.8)   
      Median (interquartile range) 66 (49–75) 67 (48–75) 69 (51–77) 67 (51–80) 71 (54–79) 64 (49–80) 69 (57–80) 67 (53–79)   
    Men (%) 45.8 55.1 47.1 47.0 50.0 48.4 50.0 51.6 .83 .27 
    White (%) 96.2 97.2 90.7 93.6 95.4 96.0 94.7 92.4 .08 .10 
  Recent* medical characteristics (%)           
    Body mass index class           
      <25 kg/m2 39.0 38.6 33.8 30.9 28.1 34.8 28.9 27.6 .01 .04 
      25–30 kg/m2  30.8 36.2 36.4 35.8 35.1 28.1 31.6 30.6 .60 .97 
      >30 kg/m2  30.1 25.2 29.9 33.3 36.8 37.1 39.5 41.8 .002 .04 
    Congestive heart failure 18.9 9.7 8.7 13.9 6.8 4.0 10.7 8.1 <.001 .003 
    Myocardial infarction 2.8 0.6 3.8 3.5 6.8 1.6 3.8 3.7 .14 .63 
    Stroke 4.2 1.7 9.6 5.2 6.8 1.6 0.6 1.2 .26 .12 
    Chronic obstructive pulmonary disease 25.9 19.3 19.2 20.9 10.2 26.2 32.7 29.8 .13 .41 
    Diabetes 15.6 11.4 17.3 16.5 13.6 19.0 19.2 26.7 .003 .01 
    Malignancy 25.9 25.0 11.5 13.9 9.1 15.1 19.2 16.8 <.001 .03 
Trauma/fracture  4.2 5.1 12.5 12.2 12.5 8.7 4.5 8.1 .07 .12 
    Hormone replacement therapy/oral 3.5 6.3 36.4 26.2 6.8 9.2 2.6 6.4 .32 .45 
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 Study year P value 
 1985/1986 
(n=617) 
1988/1989 
(n=618) 
1999 
(n=539) 
2001 
(n=597) 
2003 
(n=554) 
2005 
(n=608) 
2007 
(n=698) 
2009 
(n=794) 
Trend 
test 
1985/86 
vs. 2009 
contraceptives† 
    Post partum†  2.6 0 0 0 0 0 0 0 .01 .27 
    Any surgery, including index admission 15.6 16.5 17.3 15.7 10.2 21.4 16.7 17.4 .61 .64 
  Venous thromboembolism characteristics (%)           
    Type of venous thromboembolism event            
      Pulmonary embolism alone 16.5 15.3 12.5 20.0 13.6 16.7 17.3 23.6 .10 .09 
      Pulmonary embolism and deep vein 
thrombosis 
9.4 10.2 13.5 9.6 8.0 11.1 12.8 13.7 .20 .20 
      Lower-extremity deep vein thrombosis alone 74.1 74.4 74.0 70.4 78.4 72.2 69.9 62.7 .02 .02 
    Community acquired 91.0 91.5 86.5 85.2 86.4 82.5 82.7 77.6 <.001 <.001 
  Hospital encounter§ (%)           
    Admitted to hospital 100 100 78.8 63.5 68.2 70.6 65.4 73.3 <.001 <.001 
    If admitted, length of stay, days          <.001 <.001 
      Mean (standard deviation) 11.9 (11.3) 10.9 (7.8) 7.4 (8.4) 7.0 (9.3) 6.4 (7.0) 6.7 (5.9) 9.5 (10.4) 6.3 (8.0)   
      Median (interquartile range) 9 (7–13) 9 (7–13) 5 (4–8) 5 (3–8) 4 (2–7) 5 (3–8) 6 (3–10) 3 (2–7)   
*Recent defined as <6 months in 1980s cohort, <3 months in 1999–2007 cohort. †Among women. §Reflecting the standard care for the treatment of acute venous 
thromboembolism in 1980s, cohorts 85/86 and 88/89 included only inpatients diagnosed with acute venous thromboembolism.  
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Table 2.2 Annual event rates (per 100,000) of clinically recognized acute venous thromboembolism among Worcester 
metropolitan statistical area residents (1985–2009) 
 
 Rate (95% confidence interval) 
 1985/1986 1988/1989 1999 2001 2003 2005 2007 2009 
First-time venous 
thromboembolism at index visit 
        
  Crude 71 (63–80) 78 (69–87) 91 (83–100) 101 (92–110) 98 (89–107) 101 (92–110) 113 (104–123) 133 (123–143) 
  Adjusted* 73 (64–82) 81 (72–91) 95 (86–104) 106 (96–115) 103 (94–112) 105 (95–114) 119 (109–129) 133 (122–143) 
  Incidence rate ratio † Reference 
group 
1.1 (0.9–1.3) 1.3 (1.1–1.5) 1.4 (1.2–1.6) 1.4 (1.2–1.6) 1.4 (1.2–1.6) 1.6 (1.4–1.8) 1.9 (1.6–2.2) 
First-time pulmonary embolism ± 
deep vein thrombosis at index 
visit 
        
  Crude 23 (19–28) 22 (18–27) 29 (24–34) 36 (31–41) 33 (28–39) 48 (42–54) 56 (50–63) 64 (57–72) 
  Adjusted* 24 (19–29) 23 (18–28) 30 (25–35) 37 (32–43) 35 (30–41) 50 (44–57) 59 (52–66) 65 (58–72) 
  Incidence rate ratio † Reference 
group 
1.0 (0.7–1.3) 1.2 (1.0–1.6) 1.5 (1.2–2.0) 1.4 (1.1–1.9) 2.1 (1.6–2.7) 2.4 (1.9–3.1) 2.8 (2.2–3.5) 
First-time deep vein thrombosis 
alone at index 
        
  Crude 48 (41–55) 55 (48–63) 62 (56–70) 65 (58–73) 64 (57–72) 53 (47–60) 57 (51–64) 68 (61–76) 
  Adjusted* 49 (42–56) 58 (50–66) 65 (58–72) 68 (61–76) 68 (60–75) 54 (48–61) 60 (53–67) 68 (60–75) 
  Incidence rate ratio † Reference 
group 
1.1 (0.9–1.4) 1.3 (1.1–1.6) 1.4 (1.1–1.6) 1.3 (1.1–1.6) 1.1 (0.9–1.3) 1.2 (1.0–1.4) 1.4 (1.2–1.7) 
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 Rate (95% confidence interval) 
 1985/1986 1988/1989 1999 2001 2003 2005 2007 2009 
Recurrent venous 
thromboembolism at index visit 
        
  Crude 37 (31–44) 31 (26–37) 22 (18–26) 24 (20–29) 18 (15–23) 26 (22–31) 33 (28–38) 34 (29–39) 
  Adjusted* 39 (32–45) 32 (27–38) 23 (19–28) 25 (21–30) 19 (15–23) 28 (23–32) 35 (29–40) 35 (29–40) 
  Incidence rate ratio † Reference 
group 
0.8 (0.6–1.1) 0.6 (0.5–0.8) 0.6 (0.5–0.8) 0.5 (0.4–0.6) 0.7 (0.6–0.9) 0.9 (0.7–1.1) 0.9 (0.7–1.1) 
Recurrent pulmonary embolism ± 
deep vein thrombosis at index 
visit 
        
  Crude 10 (7–13) 8 (5–11) 6 (4–8) 7 (5–10) 4 (2–6) 7 (5–10) 10 (7–13) 13 (10–16) 
  Adjusted* 10 (7–13) 8 (5–11) 6 (4–8) 8 (5–10) 4 (2–6) 8 (5–10) 11 (8–14) 13 (10–17) 
  Incidence rate ratio † Reference 
group 
0.8 (0.5–1.3) 0.6 (0.4–1.0) 0.7 (0.5–1.2) 0.4 (0.2–0.7) 0.8 (0.5–1.2) 1.0 (0.7–1.6) 1.3 (0.9–2.0) 
Recurrent deep vein thrombosis 
alone at index visit 
        
  Crude 28 (23–33) 23 (19–28) 16 (13–20) 17 (14–21) 14 (11–18) 19 (15–23) 23 (19–27) 21 (17–26) 
  Adjusted* 29 (23–34) 24 (19–29) 17 (13–21) 18 (14–22) 15 (12–19) 20 (16–24) 24 (20–29) 21 (17–25) 
 Incidence rate ratio† Reference 
group 
0.8 (0.6–1.1) 0.6 (0.4–0.8) 0.6 (0.5–0.8) 0.5 (0.4–0.7) 0.7 (0.5–0.9) 0.8 (0.6–1.1) 0.8 (0.6–1.0) 
*Directly age- and sex-adjusted to the 2000 United States white population. †Based on Poisson regression adjusted by age and sex. 
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Table 2.2s Annual event rates (per 100,000) of clinical recognized acute venous thromboembolism among Worcester 
metropolitan statistical area residents by sex and age (1985–2009) 
 
 Rate (95% CI) 
 1985/1986 1988/1989 1999 2001 2003 2005 2007 2009 
First-time venous thromboembolism at index visit 
  Female residents (per age group in years) 
    <40 11 (6–19) 13 (7–20) 13 (8–20) 18 (12–26) 22 (15–30) 30 (22–41) 21 (14–30) 23 (16–32) 
    40s 10 (2–31) 32 (14–65) 56 (35–83) 85 (59–118) 63 (42–93) 98 (70–133) 66 (44–96) 87 (61–121) 
    50s 53 (27–94) 74 (42–121) 119 (82–166) 122 (85–171) 134 (95–184) 115 (79–162) 126 (88–175) 176 (130–232) 
    60s 161 (113–224) 168 (118–231) 198 (139–274) 282 (210–371) 180 (124–253) 264 (194–351) 246 (179–330) 240 (174–323) 
    70s 280 (204–377) 331 (247–435) 357 (275–456) 351 (270–449) 392 (306–496) 309 (233–402) 368 (285–469) 440 (348–549) 
    80+ 443 (321–597) 480 (353–639) 640 (513–789) 647 (520–797) 493 (383–626) 578 (458–720) 732 (596–891) 794 (651–958) 
    Female, crude 70 (59–82) 81 (69–94) 100 (88–113) 114 (101–128) 101 (89–114) 115 (103–129) 116 (103–130) 143 (128–158) 
    Female, adjusted* 70 (58–81) 82 (70–95) 103 (91–116) 118 (104–132) 105 (92–118) 118 (104–131) 120 (106–134) 138 (123–152) 
  Male residents (per age group in years)  
    <40 17 (10–26) 16 (10–24) 20 (13–28) 12 (8–19) 18 (12–26) 21 (14–30) 20 (14–29) 23 (16–32) 
    40s 49 (24–88) 38 (17–74) 51 (32–78) 67 (44–97) 91 (64–126) 62 (40–91) 99 (71–135) 145 (110–187) 
    50s 70 (38–119) 93 (56–148) 94 (62–138) 149 (107–203) 181 (134–239) 153 (111–207) 149 (107–203) 196 (147–257) 
    60s 230 (165–313) 202 (141–280) 220 (153–306) 247 (176–338) 316 (234–418) 247 (176–338) 412 (317–527) 392 (300–503) 
    70s 373 (263–513) 459 (336–612) 424 (320–553) 333 (241–449) 333 (241–449) 341 (248–458) 333 (241–449) 300 (213–410) 
    80+ 469 (282–737) 488 (296–760) 571 (405–785) 751 (557–992) 457 (310–651) 490 (337–689) 898 (683–1159) 816 (613–1067) 
    Male, crude 73 (61–86) 74 (62–88) 81 (70–94) 87 (76–100) 94 (82–107) 86 (74–98) 111 (98–125) 121 (108–136) 
    Male, adjusted* 77 (64–90) 80 (67–94) 86 (74–99) 93 (80–106) 101 (87–114) 91 (78–104) 119 (104–133) 127 (112–142) 
  All residents 
    All, crude 71 (63–80) 78 (69–87) 91 (83–100) 101 (92–110) 98 (89–107) 101 (92–110) 113 (104–123) 133 (123–143) 
    All, adjusted† 73 (64–82) 81 (72–91) 95 (86–104) 106 (96–115) 103 (94–112) 105 (95–114) 119 (109–129) 133 (122–143) 
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Table 2.2s Annual event rates (per 100,000) of clinical recognized acute venous thromboembolism among Worcester 
metropolitan statistical area residents by sex and age (1985–2009) (continued) 
 
 Rate (95% CI) 
 1985/1986 1988/1989 1999 2001 2003 2005 2007 2009 
First-time pulmonary embolism±deep vein thrombosis at index visit 
  Female residents (per age group in years) 
    <40 5 (2–10) 5 (2–10) 1 (0–5) 4 (2–9) 9 (5–15) 18 (12–26) 9 (5–15) 9 (5–15) 
    40s 0 (0–0) 6 (1–26) 34 (19–57) 21 (10–40) 29 (15–50) 45 (27–70) 48 (29–74) 42 (25–67) 
    50s 11 (2–34) 39 (18–75) 42 (22–73) 46 (25–78) 54 (31–87) 57 (34–92) 65 (39–102) 80 (51–120) 
    60s 62 (35–104) 46 (23–83) 54 (27–98) 114 (71–174) 66 (35–114) 132 (85–196) 90 (53–145) 162 (109–232) 
    70s 69 (35–122) 106 (62–169) 119 (75–180) 107 (66–165) 131 (84–194) 125 (80–187) 184 (128–258) 256 (187–341) 
    80+ 140 (78–235) 148 (83–244) 146 (91–224) 270 (191–371) 154 (97–233) 231 (159–326) 385 (289–504) 331 (243–442) 
    Female, crude 21 (16–29) 26 (20–34) 30 (24–38) 40 (33–49) 37 (30–45) 53 (44–62) 58 (49–68) 71 (61–82) 
    Female, adjusted* 21 (15–27) 27 (20–34) 31 (24–39) 42 (33–50) 38 (30–46) 54 (45–64) 60 (50–70) 69 (59–80) 
  Male residents (per age group in years) 
    <40 3 (1–8) 3 (1–7) 6 (3–11) 2 (1–6) 4 (2–9) 10 (5–16) 7 (4–13) 7 (3–12) 
    40s 24 (9–55) 10 (2–33) 8 (2–21) 13 (5–29) 27 (14–47) 35 (19–58) 35 (19–58) 62 (40–91) 
    50s 27 (10–61) 23 (8–56) 31 (15–59) 63 (37–100) 55 (31–90) 79 (50–119) 59 (34–95) 94 (62–138) 
    60s 86 (49–141) 49 (23–93) 76 (40–131) 110 (65–174) 110 (65–174) 151 (97–225) 268 (193–362) 192 (131–274) 
    70s 107 (55–191) 122 (65–209) 175 (111–262) 133 (79–211) 133 (79–211) 158 (98–242) 183 (118–272) 166 (105–252) 
    80+ 206 (94–399) 113 (38–268) 180 (95–311) 245 (143–394) 114 (51–224) 196 (107–332) 424 (284–612) 441 (297–631) 
    Male, crude 25 (18–33) 18 (13–25) 27 (21–34) 31 (24–38) 30 (23–37) 43 (35–52) 54 (45–64) 57 (48–67) 
    Male, adjusted* 27 (19–35) 20 (13–27) 29 (22–36) 33 (25–41) 32 (25–40) 46 (37–55) 59 (48–69) 60 (50–71) 
  All residents 
    All, crude 23 (19–28) 22 (18–27) 29 (24–34) 36 (31–41) 33 (28–39) 48 (42–54) 56 (50–63) 64 (57–72) 
    All, adjusted† 24 (19–29) 23 (18–28) 30 (25–35) 37 (32–43) 35 (30–41) 50 (44–57) 59 (52–66) 65 (58–72) 
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Table 2.2s Annual event rates (per 100,000) of clinical recognized acute venous thromboembolism among Worcester 
metropolitan statistical area residents by sex and age (1985–2009) (continued) 
 
 Rate (95% CI) 
 1985/1986 1988/1989 1999 2001 2003 2005 2007 2009 
First-time deep vein thrombosis alone at index 
  Female residents (per age group in years) 
    <40 7 (3–13) 8 (4–15) 11 (7–18) 13 (8–21) 13 (8–20) 13 (8–20) 12 (7–19) 14 (9–22) 
    40s 10 (2–31) 26 (10–56) 21 (10–40) 63 (42–93) 34 (19–57) 53 (33–80) 19 (8–36) 45 (27–70) 
    50s 42 (20–80) 35 (15–70) 76 (48–116) 76 (48–116) 80 (51–120) 57 (34–92) 61 (36–97) 96 (63–139) 
    60s 99 (62–149) 122 (80–177) 144 (95–210) 168 (114–239) 114 (71–174) 132 (85–196) 156 (104–225) 78 (44–129) 
    70s 211 (146–297) 225 (157–313) 238 (172–320) 244 (177–327) 262 (193–348) 184 (128–258) 184 (128–258) 184 (128–258) 
    80+ 303 (205–433) 332 (229–468) 493 (383–626) 378 (283–495) 339 (250–451) 347 (256–460) 347 (256–460) 462 (356–591) 
    Female, crude 48 (39–59) 55 (45–66) 70 (60–81) 74 (64–85) 64 (55–75) 63 (53–73) 57 (49–68) 72 (62–83) 
    Female, adjusted† 49 (39–59) 55 (45–66) 72 (61–83) 76 (65–87) 67 (56–77) 63 (53–73) 60 (50–70) 69 (58–79) 
  Male residents (per age group in years) 
    <40 13 (8–21) 13 (7–21) 14 (9–21) 10 (6–17) 13 (8–20) 12 (7–19) 13 (8–20) 16 (10–24) 
    40s 24 (9–55) 28 (11–59) 43 (25–68) 54 (34–81) 64 (42–94) 27 (14–47) 64 (42–94) 83 (57–116) 
    50s 43 (19–83) 70 (38–119) 63 (37–100) 86 (56–128) 126 (88–175) 75 (46–114) 90 (59–133) 102 (68–147) 
    60s 144 (94–212) 152 (101–222) 144 (92–216) 137 (87–208) 206 (142–290) 96 (55–157) 144 (92–216) 199 (136–282) 
    70s 265 (175–386) 337 (234–471) 250 (172–352) 200 (131–292) 200 (131–292) 183 (118–272) 150 (92–232) 133 (79–211) 
    80+ 263 (131–474) 375 (212–619) 392 (257–573) 506 (350–709) 343 (219–514) 294 (180–454) 473 (324–670) 375 (244–553) 
    Male, crude 48 (39–59) 56 (46–68) 54 (45–64) 56 (47–67) 64 (54–75) 43 (35–52) 57 (48–68) 65 (55–76) 
    Male, adjusted* 50 (39–60) 61 (49–72) 58 (48–68) 60 (49–70) 69 (58–80) 45 (36–54) 60 (50–70) 67 (56–78) 
  All residents 
    All, crude 48 (41–55) 55 (48–63) 62 (56–70) 65 (58–73) 64 (57–72) 53 (47–60) 57 (51–64) 68 (61–76) 
    All, adjusted† 49 (42–56) 58 (50–66) 65 (58–72) 68 (61–76) 68 (60–75) 54 (48–61) 60 (53–67) 68 (60–75) 
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Table 2.2s Annual event rates (per 100,000) of clinical recognized acute venous thromboembolism among Worcester 
metropolitan statistical area residents by sex and age (1985–2009) (continued) 
 
 Rate (95% CI) 
 1985/1986 1988/1989 1999 2001 2003 2005 2007 2009 
Recurrent venous thromboembolism at index visit 
  Female residents (per age group in years) 
    <40 9 (5–16) 5 (2–10) 4 (1–8) 3 (1–7) 1 (0–5) 4 (1–8) 2 (1–6) 5 (2–10) 
    40s 45 (23–82) 19 (7–46) 8 (2–21) 16 (7–33) 11 (4–25) 32 (17–54) 11 (4–25) 11 (4–25) 
    50s 18 (5–45) 32 (13–66) 34 (17–63) 38 (20–68) 23 (10–47) 34 (17–63) 42 (22–73) 31 (14–58) 
    60s 95 (60–145) 66 (37–109) 66 (35–114) 36 (15–74) 42 (19–82) 42 (19–82) 84 (48–137) 78 (44–129) 
    70s 119 (73–186) 96 (55–158) 77 (43–128) 77 (43–128) 89 (52–143) 83 (48–136) 101 (61–158) 119 (75–180) 
    80+ 185 (111–290) 111 (57–197) 108 (62–176) 170 (109–252) 77 (40–137) 139 (85–215) 223 (153–316) 185 (122–271) 
    Female, crude 38 (31–48) 26 (20–34) 22 (17–29) 25 (19–32) 18 (13–24) 27 (21–34) 32 (25–39) 32 (25–39) 
    Female, adjusted* 40 (31–49) 27 (20–35) 24 (17–30) 26 (19–32) 19 (13–25) 27 (21–34) 33 (26–41) 32 (25–39) 
  Male residents (per age group in years) 
    <40 10 (5–17) 16 (10–24) 3 (1–7) 3 (1–7) 5 (2–10) 6 (3–11) 3 (1–7) 5 (2–10) 
    40s 28 (11–59) 17 (5–44) 27 (14–47) 21 (10–40) 11 (4–25) 19 (8–37) 21 (10–40) 37 (21–61) 
    50s 35 (15–72) 51 (25–93) 20 (7–43) 71 (43–109) 31 (15–59) 43 (23–75) 75 (46–114) 59 (34–95) 
    60s 111 (68–172) 74 (40–125) 48 (21–94) 41 (17–85) 27 (9–65) 76 (40–131) 124 (76–191) 131 (81–200) 
    70s 201 (124–308) 172 (102–273) 158 (98–242) 92 (49–158) 83 (43–148) 83 (43–148) 158 (98–242) 108 (61–180) 
    80+ 131 (48–295) 188 (82–374) 65 (22–155) 114 (51–224) 180 (95–311) 228 (131–373) 163 (84–290) 196 (107–332) 
    Male, crude 36 (28–45) 36 (28–45) 21 (16–28) 23 (18–30) 19 (14–25) 26 (20–33) 34 (27–42) 36 (29–44) 
    Male, adjusted* 38 (28–47) 38 (29–47) 23 (16–29) 25 (18–31) 20 (14–26) 28 (21–35) 37 (29–45) 37 (29–45) 
  All residents 
    All, crude 37 (31–44) 31 (26–37) 22 (18–26) 24 (20–29) 18 (15–23) 26 (22–31) 33 (28–38) 34 (29–39) 
    All, adjusted† 39 (32–45) 32 (27–38) 23 (19–28) 25 (21–30) 19 (15–23) 28 (23–32) 35 (29–40) 35 (29–40) 
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Table 2.2s Annual event rates (per 100,000) of clinical recognized acute venous thromboembolism among Worcester 
metropolitan statistical area residents by sex and age (1985–2009) (continued) 
 
 Rate (95% CI) 
 1985/1986 1988/1989 1999 2001 2003 2005 2007 2009 
Recurrent pulmonary embolism±deep vein thrombosis at index visit 
  Female residents (per age group in years) 
    <40 2 (0–6) 0 (0–0) 1 (0–5) 1 (0–5) 0 (0–0) 1 (0–3) 1 (0–5) 1 (0–5) 
    40s 6 (1–26) 6 (1–26) 0 (0–0) 3 (0–12) 3 (0–12) 5 (1–17) 3 (0–12) 3 (0–12) 
    50s 7 (1–28) 7 (1–28) 23 (10–47) 19 (7–42) 8 (2–25) 11 (3–31) 8 (2–25) 4 (0–18) 
    60s 30 (12–61) 13 (3–37) 24 (8–57) 6 (1–28) 6 (1–28) 12 (2–38) 36 (15–74) 42 (19–82) 
    70s 32 (12–72) 28 (9–66) 12 (2–38) 30 (11–65) 30 (11–65) 18 (5–48) 24 (8–57) 59 (31–105) 
    80+ 37 (11–94) 59 (23–127) 23 (6–62) 39 (15–84) 8 (1–36) 54 (24–106) 54 (24–106) 108 (62–176) 
    Female, crude 9 (6–14) 7 (4–12) 7 (4–11) 8 (5–12) 4 (2–7) 7 (5–11) 9 (6–13) 14 (10–20) 
    Female, adjusted* 9 (5–14) 8 (4–12) 7 (4–11) 8 (4–12) 4 (2–7) 8 (4–11) 9 (6–13) 15 (10–20) 
  Male residents (per age group in years) 
    <40 3 (1–7) 2 (1–6) 1 (0–3) 1 (0–3) 1 (0–3) 0 (0–0) 1 (0–3) 2 (1–6) 
    40s 7 (1–27) 0 (0–0) 0 (0–0) 0 (0–0) 3 (0–12) 8 (2–21) 8 (2–21) 5 (1–17) 
    50s 8 (1–31) 16 (4–44) 8 (2–25) 16 (5–37) 8 (2–25) 20 (7–43) 24 (10–49) 20 (7–43) 
    60s 29 (11–65) 16 (4–46) 14 (3–44) 14 (3–44) 0 (0–0) 21 (6–55) 41 (17–85) 48 (21–94) 
    70s 57 (22–123) 72 (31–143) 33 (11–79) 42 (16–91) 8 (1–39) 25 (7–67) 50 (21–103) 42 (16–91) 
    80+ 56 (11–180) 19 (1–113) 16 (1–76) 49 (14–131) 65 (22–155) 49 (14–131) 49 (14–131) 49 (14–131) 
    Male, crude 10 (6–15) 8 (5–14) 4 (2–8) 6 (4–10) 4 (2–7) 7 (4–11) 11 (7–16) 11 (7–16) 
    Male, adjusted* 11 (6–16) 9 (5–14) 5 (2–8) 7 (3–11) 4 (1–7) 8 (4–12) 12 (7–16) 12 (7–16) 
  All residents 
    All, crude 10 (7–13) 8 (5–11) 6 (4–8) 7 (5–10) 4 (2–6) 7 (5–10) 10 (7–13) 13 (10–16) 
    All, adjusted† 10 (7–13) 8 (5–11) 6 (4–8) 8 (5–10) 4 (2–6) 8 (5–10) 11 (8–14) 13 (10–17) 
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Table 2.2s Annual event rates (per 100,000) of clinical recognized acute venous thromboembolism among Worcester 
metropolitan statistical area residents by sex and age (1985–2009) (continued) 
 
 Rate (95% CI) 
 1985/1986 1988/1989 1999 2001 2003 2005 2007 2009 
Recurrent deep vein thrombosis alone at index visit 
  Female residents (per age group in years) 
    <40 7 (4–14) 5 (2–10) 2 (1–6) 1 (0–5) 1 (0–5) 3 (1–7) 1 (0–3) 4 (1–8) 
    40s 39 (18–74) 13 (3–36) 8 (2–21) 13 (5–29) 8 (2–21) 26 (14–47) 8 (2–21) 8 (2–21) 
    50s 11 (2–34) 25 (9–56) 11 (3–31) 19 (7–42) 15 (5–36) 23 (10–47) 34 (17–63) 27 (12–53) 
    60s 66 (37–109) 53 (28–92) 42 (19–82) 30 (11–66) 36 (15–74) 30 (11–66) 48 (23–90) 36 (15–74) 
    70s 87 (48–146) 69 (35–122) 65 (35–113) 48 (22–90) 59 (31–105) 65 (35–113) 77 (43–128) 59 (31–105) 
    80+ 148 (83–244) 52 (19–116) 85 (45–147) 131 (79–205) 69 (34–127) 85 (45–147) 170 (109–252) 77 (40–137) 
    Female, crude 29 (22–37) 19 (14–26) 15 (11–21) 17 (13–23) 14 (10–19) 19 (14–25) 23 (17–29) 18 (13–23) 
    Female, adjusted* 30 (22–38) 19 (13–25) 16 (11–21) 18 (12–23) 15 (10–19) 20 (14–25) 24 (18–30) 17 (12–23) 
  Male residents (per age group in years) 
    <40 7 (3–13) 13 (8–21) 2 (1–6) 2 (1–6) 4 (2–9) 6 (3–11) 2 (1–6) 3 (1–7) 
    40s 21 (7–49) 17 (5–44) 27 (14–47) 21 (10–40) 8 (2–21) 11 (4–25) 13 (5–29) 32 (18–54) 
    50s 27 (10–61) 35 (15–72) 12 (3–31) 55 (31–90) 24 (10–49) 24 (10–49) 51 (29–85) 39 (20–70) 
    60s 82 (46–136) 58 (29–104) 34 (13–75) 27 (9–65) 27 (9–65) 55 (26–104) 82 (45–140) 82 (45–140) 
    70s 143 (81–237) 100 (50–181) 125 (73–201) 50 (21–103) 75 (37–137) 58 (26–114) 108 (61–180) 67 (31–126) 
    80+ 75 (19–211) 169 (70–348) 49 (14–131) 65 (22–155) 114 (51–224) 180 (95–311) 114 (51–224) 147 (73–268) 
    Male, crude 26 (19–34) 27 (20–36) 17 (12–23) 17 (12–23) 15 (11–21) 19 (14–25) 23 (17–30) 25 (19–32) 
    Male, adjusted* 27 (19–35) 29 (21–37) 18 (12–24) 18 (12–23) 16 (11–21) 20 (14–26) 25 (18–32) 25 (19–32) 
  All residents 
    All, crude 28 (23–33) 23 (19–28) 16 (13–20) 17 (14–21) 14 (11–18) 19 (15–23) 23 (19–27) 21 (17–26) 
    All, adjusted† 29 (23–34) 24 (19–29) 17 (13–21) 18 (14–22) 15 (12–19) 20 (16–24) 24 (20–29) 21 (17–25) 
*Directly age–adjusted to the 2000 U.S. white population. 
†Directly age– and sex–adjusted to the 2000 US white population. 
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Table 2.3 Diagnostic methods for venous thromboembolism: the Worcester venous thromboembolism study (1985–2009) 
 Study year P value 
 1985/1986 
(n=617) 
1988/1989 
(n=618) 
1999 
(n=539) 
2001 
(n=597) 
2003 
(n=554) 
2005 
(n=608) 
2007 
(n=698) 
2009 
(n=794) 
Trend 
Test 
1985/86 vs 
2009 
First-time event at index, n (%) n=405 n=442 n=435 n=482 n=466 n=482 n=542 n=633   
  Any invasive* diagnostic method 237 (58.5) 206 (46.6) 6 (1.4) 18 (3.7) 9 (1.9) 14 (2.9) 11 (2.0) 15 (2.4) <.001 <.001 
  Any non-invasive diagnostic method 285 (70.4) 335 (75.8) 406 (93.3) 456 (94.6) 453 (97.2) 477 (99.0) 535 (98.7) 615 (97.2) <.001 <.001 
Diagnostic tests in patients with deep vein 
thrombosis (%) 
n=307 n=344 n=366 n=383 n=378 n=345 n=380 n=451   
  Venogram  67.8 54.9 0.5 1.6 0.8 2.0 1.1 0.7 <.001 <.001 
  Impedance plethysmography  57.7 53.2 0 0 0 0 0 0 <.001 <.001 
  Duplex/ultrasound scan  0.3 36.3 92.9 91.6 94.4 93.0 91.3 97.8 <.001 <.001 
  Computed tomography 0 0 3.3 7.0 6.9 4.9 10.3 2.9 <.001 .003 
  Magnetic resonance imaging 0 0 0 0 0.3 7.8 9.2 0.7 <.001 .28 
  Any of above tests  94.8 96.8 95.4 95.6 97.6 99.4 100 99.1 <.001 <.001 
Diagnostic tests in patients with pulmonary 
embolism (%) 
n=131 n=127 n=137 n=170 n=159 n=228 n=268 n=307   
  Pulmonary angiogram  16.8 11.0 2.2 2.4 2.5 2.6 2.6 3.9 <.001 <.001 
  Lung scan  80.9 88.2 59.1 40.0 19.5 24.1 11.2 7.5 <.001 <.001 
  Spiral computed tomography 0 0 24.8 60.6 79.2 80.7 86.9 87.3 <.001 <.001 
  Magnetic resonance imaging 0 0 0 0 0 0.4 0 0.3 .33 1.0 
  Any of above tests  90.1 93.7 92.7 95.3 97.5 98.7 97.8 96.4 <.001 .008 
Recurrent event at index, n (%) n=212 n=176 n=104 n=115 n=88 n=126 n=156 n=161   
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 Study year P value 
 1985/1986 
(n=617) 
1988/1989 
(n=618) 
1999 
(n=539) 
2001 
(n=597) 
2003 
(n=554) 
2005 
(n=608) 
2007 
(n=698) 
2009 
(n=794) 
Trend 
Test 
1985/86 vs 
2009 
  Any invasive* diagnostic method 108 (50.9) 63 (35.8) 0 1 (0.9) 1 (1.1) 6 (4.8) 6 (3.8) 1 (0.6) <.001 <.001 
  Any non-invasive diagnostic method 126 (59.4) 122 (69.3) 97 (93.3) 107 (93.0) 85 (96.6) 124 (98.4) 153 (98.1) 158 (98.1) <.001 <.001 
Diagnostic tests in patients with deep vein 
thrombosis (%) 
n=177 n=149 n=91 n=92 n=76 n=105 n=129 n=123   
  Venogram  49.7 39.6 0 1.1 1.3 3.8 2.3 0 <.001 <.001 
  Impedance plethysmography  47.5 49.7 0 0 0 0 0 0 <.001 <.001 
  Duplex/ultrasound scan  0 32.2 94.5 92.4 93.4 96.2 89.1 97.6 <.001 <.001 
  Computed tomography 0 0 1.1 1.1 6.6 2.9 7.0 4.1 <.001 .01 
  Magnetic resonance imaging 0 0 0 0 0 6.7 11.6 4.1 <.001 .01 
  Any of above tests  83.6 87.9 94.5 94.6 98.7 99.0 99.2 99.2 <.001 <.001 
Diagnostic tests in patients with pulmonary 
embolism (%) 
n=55 n=45 n=27 n=34 n=19 n=35 n=47 n=60   
  Pulmonary angiogram  12.7 4.4 0 0 0 2.9 6.4 0 .004 .005 
  Lung scan  65.5 88.9 66.7 44.1 31.6 22.9 8.5 13.3 <.001 <.001 
  Spiral computed tomography 0 0 25.9 58.8 63.2 74.3 85.1 78.3 <.001 <.001 
  Magnetic resonance imaging 0 0 0 0 0 0 0 0 Not 
applicable 
Not 
applicable 
  Any of above tests  76.4 95.6 92.6 94.1 89.5 97.1 97.9 96.7 .001 .001 
*Invasive tests including venogram and pulmonary angiogram. 
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Figure 2.1 Age- and sex-adjusted annual event rates of (a) first-time and (b) recurrent clinical 
recognized acute VTE among WMSA residents (1985 to 2009). DVT = deep vein thrombosis; PE 
= pulmonary embolism; VTE = venous thromboembolism; WMSA = Worcester, Massachusetts, 
metropolitan statistical area. 
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Chapter III. Trends in Clinical Management and Outcomes of 
First-time Community-presenting Episodes of Venous 
Thromboembolism: The Worcester VTE Study (1999 to 2009) 
 
3.1 Abstract 
Background: Contemporary trends in health-care delivery are shifting the 
management of venous thromboembolism (VTE) events (deep vein thrombosis 
[DVT] and pulmonary embolism [PE]) from the hospital to the community, which 
may have important implications for its prevention, treatment, and outcomes.  
Methods: Population-based surveillance study monitoring trends in clinical 
epidemiology among residents of the Worcester, Massachusetts, metropolitan 
statistical area (WMSA) diagnosed with an acute VTE in all 12 WMSA hospitals. 
All patients were followed for up to 3 years after their index event. 
Results: A Total of 2234 WMSA residents were diagnosed with first-time 
community-presenting VTE (those occurring in an ambulatory setting or 
diagnosed within 24 hours of hospitalization) in biennial epriods between 1999 
and 2009. The proportion of VTE patients with PE increased from 30% in 1999 to 
48% in 2009 (P for trend <.001), and nearly all PE patients were admitted to the 
hospital for treatment over time. However, in the DVT-alone group, the proportion 
of patients admitted to the hospital decreased from 67% in 1999 to 37% in 2009 
(P for trend <.001). Among hospitalized patients, the mean length of stay 
decreased from 5.6 to 4.8 days (P for trend <.001). The proportion of VTE 
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provoked by prior surgery, pregnancy, trauma, fracture, or hospitalization, but not 
in the presence of active malignancy, decreased from 43% in 1999 to 36% in 
2009. Between 1999 and 2009, treatment of VTE shifted from warfarin and 
unfractionated heparin towards increased use of low-molecular-weight heparins 
and newer anticoagulants;  3-year cumulative event rates decreased for all-
cause mortality (41% to 26%), major bleeding (12% to 6%), and recurrent VTE 
(17% to 9%).  
Conclusions: A decade of change in VTE management was accompanied by 
improved long-term outcomes. However, rates of adverse events remained fairly 
high in our population-based surveillance study, implying that new risk-
assessment tools to identify individuals at increased risk for developing major 
adverse outcomes over the long-term are still needed. 
 
3.2 Introduction 
Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) 
and pulmonary embolism (PE), is associated with increased morbidity, functional 
disability, and mortality.1 Although hospitalized patients are at high risk for 
developing VTE,1, 48 most episodes presently occur in the community.44-45  
A substantial proportion of patients presenting with VTE in the community 
have undergone surgery or hospitalization in the preceding 3 months.3, 7, 45 
Following recent changes in health-care services and their delivery,14-15 
hospitalized patients are increasingly being discharged earlier, placing them  at 
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increased risk for  developing VTE in the community setting. Thus, it is possible 
that the proportion of community-presenting VTE has increased over time. In 
addition, advances in therapeutic strategies have made it feasible to treat most 
patients with VTE as outpatients earlier and for longer periods.32, 39-40, 42, 73 This 
change in clinical practice may have influenced subsequent short- and long-term 
outcomes. However, data generated from robust population-based surveillance 
studies describing changing trends in the clinical epidemiology of VTE are 
limited.6  
Using data from the Worcester VTE study (1999-2009), we examined 
decade-long trends in the clinical management and short- and long-term 
outcomes of patients diagnosed with first-time community-presenting VTE. 
 
3.3 Methods 
The Worcester VTE study employed population-based surveillance 
methods to monitor trends in event rates of first-time or recurrent PE and/or DVT, 
management strategies, case-fatality rates, and recurrences after the index event 
among residents (n=477,598 per 2000 Census data) of the Worcester, 
Massachusetts, metropolitan statistical area (WMSA).3, 7, 45 Computer printouts of 
all WMSA residents with health-care system encounters in which any of ICD-9 
diagnosis codes consistent with VTE (Table 1.1) had been listed in 1999, 2001, 
2003, 2005, 2007, and 2009 were screened from all 12 hospitals serving 
residents of the WMSA. Data queries encompassed all inpatient, outpatient , 
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emergency department, radiology department, and diagnostic laboratory 
encounters. Data on index and follow-up events in medical records were 
reviewed by trained abstractors and validated by clinicians retrospectively; follow-
up was up to 3 years for all independently validated patients. National and 
statewide death registries were reviewed to ascertain the survival status of all 
patients. 
This study was approved by the institutional review committees at 
participating hospitals. 
Definition of Index VTE 
Several ICD-9 diagnosis codes were used to screen and identify eligible 
acute cases of PE and/or DVT (Table 1.1). Patients were classified as first-time 
VTE or previously diagnosed (recurrent) VTE at the time of their index visit based 
on whether they had a history of VTE noted in their medical records. Ambulatory 
patients presenting to all central MA hospitals with signs and symptoms 
consistent with VTE, or diagnosed with VTE within 24 hours of hospital 
presentation, were considered as community-presenting VTE patients.45 Three 
etiologic categories of VTE were defined:7 (1) cancer-associated VTE was a VTE 
occurring in the presence of an active malignancy; (2) provoked VTE was a VTE 
occurring within 3 months of surgery, pregnancy, trauma, fracture, or 
hospitalization, but not in the presence of active malignancy; and (3) unprovoked 
(idiopathic) VTE was a VTE occurring in the absence of any provoking factors 
and active malignancy.  
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Only first-time community-presenting episodes of VTE were examined in 
this analysis. Patients diagnosed with upper-extremity DVT alone were excluded 
due to important differences in the natural history of upper-extremity versus 
lower-extremity DVT.52-53   
Adverse Events after Index VTE 
Recurrence of VTE was classified using criteria similar to those employed 
for the index event, but required the occurrence of thrombosis in a previously 
uninvolved venous (recurrent DVT) or pulmonary segment (recurrent PE). 
Recurrent VTE was classified as the first occurrence of DVT or PE after the index 
VTE. 
Episodes of major bleeding that may have occurred for patients in the 
study years of 1999, 2001, and 2003 were defined as any episode of bleeding 
requiring transfusion of ≥2 units of packed red blood cells (RBCs), or causing a 
prolonged or subsequent hospitalization (including stroke, myocardial infarction) 
or death. To be consistent with International Society of Thrombosis and 
Haemostasis criteria,51 our definition for major bleeding was revised for the 2005, 
2007, and 2009 cohorts as the following: clinically overt bleeding resulting in 
death; located in a critical site (intracranial, intraocular, retroperitoneal, intra-
articular, pericardial, muscular with compartment syndrome); required transfusion 
of ≥2 units of packed RBCs; or resulted in a hemoglobin drop of ≥20 g/L. 
Statistical Analysis 
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Categorical variables are reported as frequencies and percentages and 
continuous variables as means, standard deviations, medians, and interquartile 
ranges. Cochran-Armitage tests for binomial variables, Mantel-Haenzel tests for 
multinomial variables, and linear regression models for continuous variables 
were used to examine trends during the study years. Differences in the 
characteristics, management, and outcomes of patients diagnosed with VTE in 
2009 versus those in 1999 were examined using the chi-square or Fisher’s exact 
test for categorical variables and the Wilcoxon rank-sum test for continuous 
variables. 
To further evaluate whether study year at the time of VTE presentation 
was associated with our pre-specified outcomes during the 3-year follow-up, 
including occurrence of recurrent VTE, major bleeding, and all-cause mortality, 
Kaplan-Meier curves with log-rank tests and multivariable Cox proportional 
hazard regressions were constructed. Multivariable Cox proportional hazard 
regressions controlled for age, sex, diagnosis of PE with/without (±) DVT, and 
medical history within 3 months before the index event (congestive heart failure, 
myocardial infarction, stroke, cardiac procedure, chronic obstructive pulmonary 
disease, diabetes, active cancer, serious infection, trauma, major fracture, 
surgery, non-surgical-related hospitalization). Patients who experienced major 
bleeding before the development of a recurrent VTE over the course of follow-up 
were excluded from the recurrent VTE regression model; patients with recurrent 
VTE prior to major bleeding during follow-up were excluded from the major 
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bleeding regression model. All follow-up data were censored at the last contact 
(3 years) for mortality, and at the earliest of death or the last contact (3 years) for 
major bleeding and recurrent VTE following the index event.   
All analyses were performed using SAS 9.2 (SAS Institute Inc., Cary, NC) 
and statistical significance level was pre-specified as α=.05 (2-sided). 
 
3.4 Results 
Over the 10-year study period, 3039 WMSA residents were diagnosed 
with a first episode of acute PE±DVT or lower-extremity DVT alone. Of these, 
2,334 (77%), ranging from a low of 74% in 1999 to a high of 80% in 2007, and 
77% in 2009 (P for trend .04), were community-presenting and serve as the 
focus of this report. 
Patient Characteristics  
Among the 2, 334 patients, 43% were men, 94% were white, and their 
mean age was 63.4(±18.2) years. One third (32%) of patients were treated only 
in an ambulatory setting.  
Patient baseline characteristics are shown in Table 3.1. Over time, the 
mean age of patients decreased and an increasing proportion were overweight. 
There was a decline in the  frequency of patients with previously diagnosed heart 
failure, myocardial infarction, stroke, trauma, major fracture, surgery, or non-
surgical hospitalization, with an increased frequency of patients with previously 
diagnosed chronic obstructive pulmonary disease. Although there was no 
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detectable trend in the proportion of cancer-associated VTE, the proportion of 
provoked VTE decreased, concomitant with  increases in the proportion of 
persons with unprovoked VTE. The proportion of patients diagnosed with 
PE±DVT rose from 30% in 1999 to 48% in 2009, and nearly all were admitted to 
area  hospitals over time. Among the DVT-alone group, the proportion admitted 
to the hospital decreased from 67% in 1999 to 37% in 2009. A decreasing trend 
in mean length of hospitalization was detected as well.  
Prior VTE Prophylaxis 
Overall, 43% of patients had either surgery or a non-surgical-related 
hospitalization during the 3 months preceding the index VTE. Among patients 
who underwent prior surgery, the proportion who received perioperative VTE 
prophylaxis increased from 50% in 1999 to 76% in 2009, primarily due to 
increases in the receipt of pharmacologic prophylaxis (Figure 3.1A). Among 
patients who had a prior non-surgical-related hospitalization, the proportion that 
received thromboprophylaxis did not vary, remaining consistently over 80% 
(Figure 3.1B).  
Acute Treatment in the Hospital or Ambulatory Care Settings 
Between 1999 and 2009, the proportion of patients who received low-
molecular-weight heparin (LMWH) more than doubled, and the proportion who 
received unfractionated heparin (UFH) decreased (Table 3.2). We observed a 
declining trend in the initiation of warfarin during initial treatment, while there 
were no statistically significant changes in the use of inferior vena cava filters 
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during the years under study (Table 3.2). The proportion of patients who received 
any form of parenteral anticoagulant therapy other than UFH or LMWH increased 
dramatically, primarily due to use of fondaparinux.  
 At discharge from the hospital or emergency department, the proportion of 
patients who received LMWH increased from 26% in 1999 to 63% in 2009 
whereas the proportion receiving warfarin alone decreased from 57% to 27% 
(Table 3.2).  
 
Outcomes after Index Event  
Overall (the entire 10 years) cumulative mortality rates at 30 days, 1 year, 
and 3 years, respectively, were 6.8%, 21%, and 32% among all patients; 10%, 
24%, and 34% among the PE±DVT group; and 4.4%, 19%, and 31% among the 
DVT-alone group. There was a decreasing trend in all-cause mortality, primarily 
among patients diagnosed with DVT-alone (Table 3.3, Figure 3.2A).  
 Overall cumulative rates of major bleeding were 5.1%, 7.6%, and 9.5%, 
respectively, at 30 days, 1 year, and 3 years. The cumulative rates of major 
bleeding at 30 days, 1 year, and 3 years all decreased from 1999 to 2009 (Table 
3.3, Figure 3.2B). After adjustment for a variety of potentially confounding 
variables, the rate of major bleeding in 2009 was reduced by more than half 
compared with that in 1999 (Table 3.3). 
 Among all VTE patients, overall cumulative recurrence rates of VTE were 
2.9%, 7.2%, and 11% (0.6%, 2.0%, and 3.3% for recurrent PE; 2.4%, 6.1%, and 
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9.3% for recurrent DVT), respectively, at 30 days, 1 year, and 3 years. During the 
study period, a decreasing trend was observed in the frequency of recurrent VTE 
(Table 3.3, Figure 3.2 C and D). 
 
3.5 Discussion 
Among residents of central Massachusetts diagnosed with a first-time 
community-presenting VTE between 1999 and 2009, we observed significant 
decreases in all-cause mortality, major bleeding episodes, and recurrent VTE 
within 3 years of the index event. However, despite these encouraging trends, 
the frequency of major adverse events remained relatively high. These changes 
occurred concurrent with a number of other historical trends, most notably an 
increase in the occurrence of unprovoked VTEs, a change in anticoagulant 
treatment strategies, and an increase in the use of VTE prophylaxis for patients 
who had undergone surgery.  
Patient Characteristics 
Between 1999 and 2009, there was an increasing trend in the proportion 
of PE±DVT among first-time community-presenting VTE. This increasing trend 
was consistent with the findings from our prior publication, which focused on all 
patients diagnosed with first-time or recurrent VTE at the time of their index 
health encounter,74 as well as with published findings from the US Nationwide 
Inpatient Sample, commercial insurance, and Medicare databases.67-68 This 
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increasing trend may be  due, in part,  to the increased utilization of newer, high-
sensitivity, diagnostic methods.74 71 
The overall proportion of cancer-associated VTE (nearly 20%) and 
proportion of patients (43%) with a surgery or a non-surgical-related 
hospitalization within 3 months preceding the index event are consistent with 
those from another population-based observational study conducted among 
residents of Olmsted Country, Minnesota, during 1976-1990.75   
 Although the proportion of cancer-associated VTE remained constant in 
our study, there was a decrease in the proportion of patients who had a history of 
trauma, major fracture, surgery, or hospitalization for a non-surgical illness within 
3 months before their index VTE. Thus, the proportion of VTE that are not easily 
predictable or preventable (i.e., unprovoked) increased. We are not aware of 
studies reporting similar secular trends, and we hypothesize that declines in the 
proportion of provoked VTE could be related to observed improvements in 
perioperative management including VTE prophylaxis among patients who had 
prior surgery and possibly due to the increased use of sensitive diagnostic tests. 
Prior VTE Prophylaxis  
Growing awareness of VTE as a public-health problem has become the 
impetus for evidence-based practice guidelines for VTE prevention.48, 64 In 2005, 
a VTE quality measure was selected as a core measure set in the Joint 
Commission’s performance measurement and improvement initiative among 
hospitalized patients.43 These changes could have influenced clinical practice 
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towards a measurable improvement in practices and outcomes in patients at 
recognized “high” risk for VTE. Indeed, the proportion of patients who received 
any form of thromboprophylaxis among patients who had prior surgery increased 
from 50% in 1999 to 76% in 2009 in our study; although these prophylaxis 
measures were not associated with a reduction in the overall rates of index VTE, 
possibly due to competing factors (see below), increases in overall perioperative 
prophylaxis likely contributed to the observed decline in provoked VTE.  
 In a prior publication, we documented that the overall rate of VTE per 
100,000 WMSA residents increased from 1999 through 2009.74 Thus, increases 
in the proportion of unprovoked VTE represent a true increase in the population-
based rate of diagnosis of unprovoked VTE, which may be attributable to 
improved diagnostic approaches or to poorly understood increases in VTE risk 
factors. Further research is needed to better understand factors affecting the 
development of VTE in the community setting and to identify additional triggers 
and risk factors. 
Despite declining trends in the proportion of VTE patients who were either 
hospitalized or had surgery in the 3 months before their index event, this 
proportion was still approximately 40% in 2009. These patients were likely to 
have been considered at the “highest” risk for developing VTE because they had 
a VTE episode within 3 months after their surgery or hospitalization. This may 
explain why we observed a higher rate of VTE prophylaxis among these patients 
compared with the findings of a cross-sectional study based on all inpatients in a 
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sample of US hospitals.76 However, among patients recognized as being at high 
risk for VTE due to recent surgery or hospitalization in 2009, approximately 20% 
did not receive any type of VTE prophylaxis during the period of hospitalization or 
surgery.           
  A prospective registry of ,5451 patients diagnosed with ultrasound-
confirmed DVT from 183 US sites revealed that only 42% of patients who had 
hospital-acquired DVT received prophylaxis within 30 days before their index 
event.77 These collective findings suggest that VTE prophylaxis remains 
markedly underutilized despite the availability of evidence-based consensus 
guidelines.  
Acute Treatment in Hospital and Ambulatory Settings 
Use of LMWH has changed the landscape of VTE treatment by enabling 
home treatment and providing an alternative long-term anticoagulant in 
populations in whom warfarin is less effective, difficult to manage, or 
contraindicated.32, 39-40, 42, 73, 78 Accordingly, we observed an increasing trend in 
the use of LMWH, with a corresponding decrease in initial treatment with UFH 
and warfarin during the acute period. These practice changes may have 
influenced the proportion of patients admitted to the hospital for treatment among 
WMSA residents diagnosed with DVT alone. Early studies evaluating outpatient 
treatment of DVT have determined this practice to be safe and effective.78 
Presumably, recent findings and recommendations from randomized clinical trials 
(RCTs) and guidelines have influenced clinical practice as well.79-82 
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Outcomes after Index Event 
During the past three decades, major advances have occurred in 
identifying patients at risk for VTE and in the utilization of diagnostic and 
treatment strategies.1, 6, 64 The observed declining trends in all-cause mortality, 
major bleeding, and recurrent VTE within 3 years of the index event may be 
evidence of improved patient outcomes based on these advances. 
A study based on the US Nationwide Inpatient Sample detected a similar 
decreasing trend in hospital mortality rates among all hospitalized cases of PE in 
US acute care hospitals between 1998 and 2005.67 However, despite 
encouraging declining trends in all-cause mortality observed between 1999 and 
2009, the 3-year cumulative all-cause mortality rate was still 26% in 2009. While 
we cannot comment on cause-specific mortality, we suspect that most of these 
deaths were due to the influence of comorbid conditions.65 Indeed, an ongoing 
international multicenter VTE-treatment registry reported that the 3-month all-
cause mortality in patients with proven symptomatic acute VTE was 7.9%, 
whereas deaths considered as PE-related was only 1.4%.83 
The cumulative rates of major bleeding or recurrent VTE in our study were 
higher than those reported in RCTs of VTE treatment,84 in spite of the declining 
rates observed over time. These differences are likely related, in part, to the 
inclusion criteria employed in RCTs, resulting in a more narrowly defined, “less 
ill” population. In addition, therapy is more carefully monitored in RCTs than in 
the uncontrolled setting of community practice. Indeed, other observational 
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studies have reported higher rates of recurrent VTE: 5% at 1 month, 11-13% at 1 
year, 20% at 3 years, and 30-40% at 10 years after an acute episode of VTE.31, 85 
Further research is needed to develop safer and more effective treatment 
strategies that balance the benefits of treatment against the increased risk of 
bleeding. Furthermore, point-of-care, patient-specific, robust prognostic 
prediction models may be particularly helpful in guiding treatment decisions.86-88  
Study Strengths and Limitations 
The study employed population-based surveillance methods to describe 
the clinical epidemiology of VTE in WMSA residents, along with prevention and 
treatment data and changes over time therein. Although we conducted broad 
screening for cases of VTE using multiple databases, validated each potential 
case of VTE, and performed regular chart audits, we may have missed some 
cases of asymptomatic VTE. Due to the low autopsy rates in the WMSA, and the 
limited validity of death-certificate data, 3, 7 only clinically recognized cases of 
acute VTE were described and some cases of fatal PE could have been missed. 
The most important indicator of bleeding such as the need for ≥2 units of packed 
RBCs was present in both versions of the definition of major bleeding, so the 
decline in major bleeding was likely to be real. We did not collect information on 
the use of long-term anticoagulation; therefore, we could not assess the impact 
of use of various anticoagulation strategies, including the duration of therapy, on 
our principal study outcomes. 
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3.6 Conclusions 
This population-based study in residents of central Massachusetts 
confirms that most first-time VTE develop in the community setting and that this 
trend increased between 1999 and 2009. We detected an increase in incidence 
rates of unprovoked VTE, indicating the need to identify novel risk factors for this 
event. While the decreasing frequency of major adverse outcomes is reassuring, 
mortality, major bleeding, and recurrence rates remained high, suggesting that 
current treatment strategies are less than optimal. New risk-assessment tools to 
estimate the true risks and benefits associated with VTE prevention and 
treatment at the individual patient-level are needed.   
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3.7 Tables and figures 
Table 3.1 Characteristics of Patients with Community-presenting First-time VTE: 1999-2009 
 
Study Year 
 
1999 2001 2003 2005 2007 2009 P for 
Trend  
P  
1999 vs. 
2009 
No. of VTEs 320 362 353 380 431 488   
Demographic characteristics         
Age, y       .04 .02 
Mean±SD 65.9±18.1 64.6±17.4 62.3±17.9 61.9±19.1 63.3±18.3 63.0±18.2   
Median (IQR) 71 (52-80) 66 (51-79) 64 (50-77) 64 (47-79) 66 (50-79) 65 (49-79)   
Men, % 41.9 38.7 46.2 40.0 47.1 43.6 .18 .62 
White, % 95.7 95.1 93.5 94.3 95.0 92.4 .10 .06 
Recenta medical characteristics prior to index 
VTE, % 
        
BMI, kg/m2       .03 .04 
<25  34.9 32.7 24.0 35.2 28.4 25.3 .02 .01 
25-30  25.9 31.5 35.1 29.3 35.3 29.8 .43 .30 
>30 39.2 35.8 40.9 35.5 36.3 44.9 .13 .17 
Congestive heart failure 9.4 10.8 8.5 6.8 5.8 4.9 <.001 .01 
Myocardial infarction 3.4 5.5 4.0 1.3 2.8 2.0 .013 .23 
Stroke 4.7 4.4 5.1 1.1 1.6 1.0 <.001 .001 
Cardiac procedure 2.8 5.0 3.1 3.9 3.9 3.9 .75 .41 
Chronic obstructive pulmonary disease 15.3 20.7 16.4 20.8 24.1 22.7 .003 .01 
Diabetes 15.6 21.0 17.3 15.3 21.6 16.8 .82 .66 
Active malignancy 17.8 19.9 11.3 15.0 16.7 17.0 .64 .77 
Chemotherapy (among active malignancy) 54.4 56.9 60.0 57.9 52.8 41.0 .07 .12 
Trauma/fracture  16.9 23.2 13.0 8.7 7.2 7.4 <.001 <.001 
Serious infection 14.4 22.7 22.1 19.5 16.9 14.3 .10 .99 
Intensive care unit discharge 10.0 9.7 8.2 8.4 9.5 8.6 .58 .50 
HRT/oral contraceptives (among women) 24.2 23.9 17.9 12.3 8.3 12.4 <.001 <.001 
Post partum (among women)  2.2 0.9 1.6 2.2 1.3 1.5 .85 .72 
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Study Year 
 
1999 2001 2003 2005 2007 2009 P for 
Trend  
P  
1999 vs. 
2009 
Surgery before index event 26.9 28.2 21.0 23.4 20.4 18.4 <.001 .005 
Hospitalization due to non-surgical illness before 
index event 
38.4 43.4 35.1 24.2 24.1 24.6 <.001 <.001 
VTE characteristic, %         
Diagnosis of index event       <.001 <.001 
PE±DVT 30.0 34.3 33.7 48.7 48.3 47.7   
Lower extremity DVT alone 70.0 65.7 66.3 51.3 51.7 52.3   
Type of VTE event       <.001 .06 
Cancer-associated 17.8 19.9 11.3 15.0 16.7 17.0 .64 .77 
Provoked (non-cancer-associated)b 43.4 47.5 37.1 37.1 33.4 36.1 <.001 .04 
Unprovokedc 38.8 32.6 51.6 47.9 49.9 46.9 <.001 .02 
Hospital encounter, %         
Admitted to hospital 75.9 71.3 62.3 68.2 66.4 65.0 .002 <.001 
Length of stay, days       <.001 <.001 
Mean±SD 5.6±4.8 6.8±6.4 6.0±5.6 5.4±5.9 4.9±4.0 4.8±5.1   
Median (IQR) 5 (3-7) 5 (3-8) 5 (3-7) 4 (3-6) 4 (2-6) 4 (2-6)   
Admitted to hospital among patients with PE±DVT 95.8 99.2 97.5 96.2 94.7 95.7 .17 .96 
Admitted to hospital among patients with lower 
extremity DVT alone 
67.4 56.7 44.4 41.5 39.9 36.9 <.001 <.001 
 
Abbreviations: BMI, body mass index; DVT, deep vein thrombosis; HRT, hormone replacement therapy; ICU, intensive care unit; IQR, inter-quartile range; PE, pulmonary 
embolism; SD, standard deviation; VTE, venous thromboembolism. 
aRecent defined as < 3 months and prior to index VTE. 
bProvoked VTE was defined as VTE occurring with a history of a surgical procedure, pregnancy, trauma, fracture, or hospitalization within 3 months prior to index visit. 
cUnprovoked VTE was defined as VTE occurring in the absence of any of the above “provoking” factors or active malignancy (cancer-associated). 
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Table 3.2 Initial Treatment of Patients with First-time VTE Developed in a Community Setting: 1999-2009 
 
Study Year 
 
1999 2001 2003 2005 2007 2009 P for 
Trend  
P  
1999 vs. 
2009 
No. of VTEs 320 362 353 380 431 488   
Acute treatment methodsa, %         
IV/SQ UFH 65.9 52.8 41.1 35.8 33.9 29.9 <.001 <.001 
SQ LMWHb 29.1 45.9 60.1 69.5 73.3 64.5 <.001 <.001 
Other parenteral anticoagulantc  0 1.4 2.5 1.1 3.5 19.3 <.001 <.001 
IVC filter implanted prior/during 
index visit 
10.0 11.0 9.3 8.9 10.7 7.6 .23 .23 
Warfarin initiated during initial 
treatment 
76.3 69.9 67.1 55.3 52.7 56.1 <.001 <.001 
Discharge medication among 
hospital/ED survivors, % 
n = 260 n = 285 n = 277 n = 298 n = 327 n = 382   
Warfarin 80.4 79.3 81.9 76.8 82.0 75.9 .27 .18 
SQ LMWH 26.2 38.6 48.4 56.4 61.8 63.1 <.001 <.001 
Combination treatment         
Warfarin with LMWH 19.6 31.6 41.9 45.3 56.0 49.0 <.001 <.001 
Warfarin with UFH 3.8 2.5 0.4 0 0 0 <.001 <.001 
Warfarin without LMWH/UFH 56.9 45.3 39.7 31.5 26.0 27.0 <.001 <.001 
LMWH without warfarin/UFH 6.5 7.0 6.5 11.1 5.5 14.1 .002 .002 
UFH without warfarin/LMWH 2.3 1.1 0.7 0.3 0.6 0.8 .08 .17 
None of the above 10.8 12.6 10.8 11.7 11.6 9.2 .39 .50 
Abbreviations: ED, emergency department; IV, intravenous; IVC, inferior vena cava; LMWH, low molecular weight heparin; SQ, subcutaneous; UFH, unfractionated heparin. 
aInitial therapy in health-care facility (inhospital or ambulatory settings); may receive more than one parenteral anticoagulant. 
bEnoxaprain, dalteparin, tinzaparin. 
cFondaprinux, danaparoid, hirudin, argatroban, other. 
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Table 3.3 Mortality, First Episode of Major Bleeding, and Recurrent VTE after Index Event: 1999-2009 
 
Study Year 
 
1999 2001 2003 2005 2007 2009 P for 
Trend  
P  
1999 vs. 
2009 
No. of VTEs 320 362 353 380 431 488   
All patients with VTE         
Death within 1 month post index, % 8.1 6.9 4.6 7.7 7.4 6.1 .67 .29 
Death within 1 year post index, % 25.7 24.4 20.2 21.2 18.3 19.3 .007 .03 
Death within 3 years post index, % 40.9 37.8 30.9 31.6 28.8 26.4 <.001 <.001 
Hazard ratio (95% CI)a Ref 0.83 
(0.64-1.07) 
0.82 
(0.63-1.06) 
0.85 
(0.65-1.10) 
0.79 
(0.61-1.03) 
0.66 
(0.51-0.85) 
  
Patients with PE±DVT n = 96 n = 124 n = 119 n = 185 n = 208 n = 233   
Death within 1 month post index, % 13.2 10.1 6.7 10.8 11.1 9.0 .63 .26 
Death within 1 year post index, % 24.2 26.1 22.7 21.7 23.1 26.2 .84 .71 
Death within 3 years post index, % 37.5 39.5 30.3 30.8 33.7 33.9 .40 .53 
Hazard ratio (95% CI)a Ref 0.97 
(0.58-1.48) 
1.04 
(0.64-1.69) 
1.08 
(0.69-1.71) 
1.05 
(0.68-1.63) 
0.91 
(0.59-1.40) 
  
Patients with DVT alone n = 224 n = 238 n = 234 n = 195 n = 223 n = 255   
Death within 1 month post index, % 6.0 5.2 3.5 4.6 4.0 3.5 .20 .21 
Death within 1 year post index, % 26.3 23.5 19.0 20.6 13.9 12.9 <.001 <.001 
Death within 3 years post index, % 42.4 37.0 31.2 32.3 24.2 19.6 <.001 <.001 
Hazard ratio (95% CI)a Ref 0.84 
(0.61-1.14) 
0.72 
(0.53-0.99) 
0.76 
(0.54-1.06) 
0.68 
(0.48-0.96) 
0.52 
(0.36-0.74) 
  
Major bleeding          
Within 1 month post index, % 6.8 8.2 7.2 4.3 2.3 3.5 <.001 .03 
Within 1 year post index, % 9.1 11.1 9.5 9.1 4.4 4.5 <.001 .01 
Major bleeding within 3 years post 
index, % 
11.9 12.2 11.3 12.1 5.8 5.7 <.001 .002 
Hazard ratio (95% CI)a Ref 0.96 
(0.60-1.53) 
1.01 
(0.63-1.62) 
0.97 
(0.60-1.55) 
0.48 
(0.28-0.83) 
0.43 
(0.25-0.75) 
  
Recurrent VTE          
Within 1 month post index, % 5.2 1.7 5.4 2.4 2.1 1.6 .006 .004 
Within 1 year post index, % 11.4 8.4 8.9 5.6 5.6 5.3 <.001 .002 
Within 3 years post index, % 16.9 12.7 11.3 11.3 8.6 8.6 <.001 <.001 
Hazard ratio (95% CI)a Ref 0.72 
(0.46-1.12) 
0.61 
(0.38-0.96) 
0.62 
(0.39-0.97) 
0.53 
(0.34-0.85) 
0.52 
(0.33-0.85) 
  
Recurrent PE after index VTE         
Within 1 month post index, % 0.7 0.6 1.4 0.5 0.2 0.4 .30 .64 
Within within 1 year post index, % 1.6 3.2 2.9 1.6 2.1 0.8 .09 .32 
Within within 3 years post index, % 3.1 5.0 4.0 3.2 3.7 1.6 .07 .16 
Hazard ratio (95% CI)a Ref 1.59 
(0.67-3.75) 
1.51 
(0.63-3.61) 
0.96 
(0.38-2.44) 
1.40 
(0.58-3.37) 
0.73 
(0.27-1.96) 
  
Recurrent DVT after index VTE         
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Study Year 
 
1999 2001 2003 2005 2007 2009 P for 
Trend  
P  
1999 vs. 
2009 
Within 1 month post index, % 4.6 1.2 4.0 2.1 1.9 1.4 .02 .007 
Within within 1 year post index, % 10.4 6.0 7.5 5.0 4.6 4.7 .001 .002 
Within within 3 years post index, % 15.3 9.4 9.6 10.0 6.5 7.2 <.001 <.001 
Hazard ratio (95% CI)a Ref 0.55 
(0.33-0.89) 
0.47 
(0.28-0.79) 
0.57 
(0.35-0.93) 
0.39 
(0.23-0.66) 
0.40 
(0.24-0.67) 
  
Abbreviations: CI, confidence interval; DVT, deep vein thrombosis; PE, pulmonary embolism; Ref, reference group; VTE, venous thromboembolism. 
aResults from Cox proportional hazards model adjusted by age, sex, diagnosis of PE with/without (±) DVT, and medical conditions within 3 months before the index event 
(congestive heart failure, myocardial infarction, stroke, cardiac procedure, chronic obstructive pulmonary disease, diabetes, active cancer, serious infection, trauma, major 
fracture, surgery, non-surgical-related hospitalization) 
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Figure 3.1 VTE Prophylaxis before Index Event: 1999-2009 
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Figure3.2 Cumulative Incidence of (A) Death, (B) Major Bleeding, (C) Recurrent DVT, (D) Recurrent PE after Index VTE: 1999-2009 
Abbreviations: DVT, deep vein thrombosis; PE, pulmonary embolism; VTE, venous thromboembolism  
Kaplan-Meier curves by secular period account for censoring 
 
. 
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Chapter IV. Predicting Recurrence after First-time Acute Venous 
Thromboembolism 
 
4.1 Abstract 
Background: Venous thromboembolism (VTE), comprising deep vein 
thrombosis (DVT) and pulmonary embolism (PE), has multiple risk factors and 
tends to recur. Despite the benefits of anticoagulation, the prevalence of, and 
case-fatality rate associated with, recurrent VTE remains a concern over several 
years after an acute episode; it is particularly high during the acute treatment 
phase. Therefore, identifying individual risk factors associated with recurrence 
may lead to more effective secondary prevention and enhanced prognosis. 
Methods: Population-based surveillance study with 3-year follow-up among 
residents of central Massachusetts diagnosed with an acute first-time PE and/or 
lower-extremity DVT from 1999 through 2009 at in-hospital and ambulatory 
settings in all 12 central MA hospitals. Medical records were reviewed by trained 
abstractors and validated by clinicians.  
Results: The 2,989 study patients were followed for a total of 5,836 person-
years with mean follow-up duration of 23.4(±14.4) months. Mean age of the study 
popualtion was 64.3(±18.0) years, and 44% were men. The Kaplan-Meier 
estimated cumulative incidence rate of recurrent VTE  within 3 years after an 
index VTE was 15%. Multivariable Cox proportional hazard regression indicated 
that active cancer (with/without chemotherapy), a hypercoagulable state, 
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varicose vein stripping, and inferior vena cava filter placement were independent 
predictors of recurrence during short- (3-month) and long-term (3-year) follow-up. 
Risk score calculators were developed based on the 3-month prognostic models. 
Conclusions: Several independent predictors were identified that may be useful 
for estimating risk of VTE recurrence at the individual patient-level. The risk score 
calculators may assist clinicians at the index encounter in determining the 
frequency of clinical surveillance and appropriate outpatient treatment of VTE 
during the acute treatment phase. 
 
4.2 Introduction 
Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) 
and pulmonary embolism (PE), is associated with increased long-term morbidity, 
functional disability, and all-cause mortality.1 VTE has been estimated to be the 
third most common acute cardiovascular event after acute coronary syndromes 
and ischemic stroke.2 Despite advances over the past three decades in VTE 
identification, prophylaxis, and treatment, the annual event rate of VTE has 
increased over time.66-68, 74  
VTE is a disease with multiple contributory risk factors which tends to 
recur,1, 48 especially during the first three years after an acute episode.17-19 Data 
from a limited number of observational studies have suggested that the 
cumulative recurrence rate after an acute event is approximately 8% at 90 days, 
11-13% at 1 year, 20% at 3 years, and 30-40% at 10 years.31, 85 In current 
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practice, anticoagulation treatment is recommended for at least 3 months for 
nearly all patients.48 However, despite the proven benefits of anticoagulation, a 
systematic review indicated that the case-fatality rate of recurrent VTE is greater 
than 11% during the initial 3 months of acute treatment.84    
 Therefore, understanding who is at risk for developing a recurrence during 
the acute treatment phase may help clinicians to determine the optimal frequency 
of subsequent clinical surveillance and the appropriate type of outpatient 
treatment. Furthermore, the decision to continue or discontinue anticoagulation 
beyond 3 months (extended treatment phase) continues to be individually 
tailored,48 yet risk assessment tools for predicting the long-term risk of VTE 
recurrence at the individual patient-level remain limited.87   
 Inasmuch, , identifying short- and long-term risk factors associated with 
recurrent events after an acute episode of VTE may lead to improved strategies 
for VTE secondary prevention. A limited number of published studies have 
attempted to quantify the risk of, and factors associated with, VTE recurrence. 
These studies have either focused on a subset of VTE patients or used data from 
randomized clinical trials, administrative databases, or outdated observational 
cohorts that may limit their value.31, 85, 89-94  
We used population-based surveillance methods to monitor residents of 
central Massachusetts diagnosed with an acute first-time episode of PE and/or 
lower-extremity DVT on a biennial basis between 1999 and  2009. We followed 
these individuals for 3 years to quantify the magnitude of recurrent events and 
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identify predictors of short- and long-term recurrence after the index episode. Our 
risk score calculators use characteristics assessed during the index encounter to 
predict VTE recurrence during the initial 3-month acute treatment period. 
 
4.3 Methods 
The Worcester VTE study employed population-based surveillance 
methods to monitor trends in annual event rates of acute episodes of  PE and/or 
DVT, management strategies, case-fatality rates, and recurrences after the index 
event among all residents of the Worcester metropolitan statistical area (WMSA) 
(n=478,000 per 2000 Census data).3, 7, 45, 74     
 Computer printouts of all WMSA residents with health-care system 
encounters in which any ICD-9 diagnostic codes consistent with VTE (Table 1.1) 
had been listed during 1999 to 2009 on a biennial basis from all 12 hospitals 
serving residents of the WMSA were used to screen and identify index events. 
Data queries encompassed all inpatient, outpatient, emergency department, 
radiology department, and diagnostic laboratory encounters. Medical records 
related to the index and follow-up events were retrospectively reviewed by 
trained abstractors and validated by clinicians; follow-up was up to 3 years for all 
independently validated events. National and state-wide death registries were 
reviewed to ascertain the survival status of all study patients. 
The institutional review committee at each participating hospital approved 
this study. 
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Definition of Index Episode of VTE 
Several ICD-9 diagnosis codes were used to screen and identify eligible 
acute cases of PE and/or (±) DVT (Table 1.1). Patients were classified as first-
time VTE or previously diagnosed (recurrent) VTE at the time of their index visit 
based on whether they had a history of VTE noted in their medical records. 
Three etiologic categories of VTE were defined:7 (1) cancer-associated VTE was 
classified as a VTE occurring in the presence of an active malignancy; (2) 
provoked VTE was a VTE occurring within 3 months of surgery, pregnancy, 
trauma, fracture, or hospitalization, but not in the presence of active malignancy; 
and (3) unprovoked (idiopathic) VTE was classified as a VTE occurring in the 
absence of any provoking factors and active malignancy.  
In the present analyses, only patients with a first-time (incident) episode of 
VTE were included. Patients diagnosed with upper-extremity DVT alone were 
excluded due to important differences in the natural history of upper-extremity 
versus lower-extremity DVT.52-53  
Recurrence after Index Episode of VTE  
Through the retrospective review of medical records, a recurrent episode 
of VTE after the patient’s index event was defined as a first occurrence of 
thrombosis in a previously uninvolved venous (recurrent DVT) or pulmonary 
segment (recurrent PE). Due to lack of adequate sample size (Table 4.1s), a 
multivariable model using recurrent PE as the endpoint was not conducted. 
Potential Prognostic Factors 
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Potential prognostic factors included patient demographic characteristics, 
medical history within 3 months prior to the index event, type of diagnosis 
(PE±DVT versus DVT alone), clinical characteristics assessed during the index 
encounter, and acute therapy in a health-care facility (in-hospital/at discharge or 
ambulatory settings). 
 
Statistical Analysis 
The distributions of various patient characteristics assessed during the 
index encounter were described using mean, standard deviation, median and 
inter-quartile range for continuous variables and frequency with percent for 
categorical variables. Hazard ratios (HRs) and 95% confidence intervals (CIs) 
generated by the unadjusted Cox proportional hazards regression models  were 
used to describe  the relationship of potential prognostic factors to time-to-
recurrent VTE. 
The cumulative incidence rate (CIR) of VTE recurrence within 3 years 
after the patient’s index event was estimated using the Kaplan-Meier method. 
Data were censored at the time of death or last medical contact (in survivors) up 
to 3 years following the index event. The log-rank test was used to compare CIRs 
of VTE recurrence among cancer-associated, provoked, and unprovoked 
episodes of VTE since prior publications suggest that the recurrence rate among 
these three groups are different.48-49, 87 
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Since each potential prognostic factor was assessed during the index VTE 
encounter, and possible unmeasured time-dependent risk factors (e.g. duration 
of treatment) may have impacted our results, separate prognostic models for 
predicting short-term (3-month) and long-term (3-year) risks of recurrence were 
developed. In addition, due to differences between VTE patients with and without 
active cancer in the risk of recurrence and in patient management practices 
during the acute treatment period, sensitivity analyses were conducted and a 
separate 3-month prognostic model among non-cancer patients was developed. 
Although we attempted to develop a 3-month prognostic model among cancer 
patients, due to the lack of statistical power, a multivariable Cox regression 
model could not be constructed. Therefore, three prognostic models for 
predicting risk of VTE recurrence after the index event (predicting 3-year risk and 
3-month risk among all patients; predicting 3-month risk among patients without 
active cancer) were reported in the current study.     
 The methods used to develop the prognostic models were as follows: the 
full model included all potential prognostic factors identified by unadjusted Cox 
proportional hazard regression analyses with p-values ≤0.1; multivariable Cox 
regression with backward selection was then used to select the final independent 
predictors (p<0.05). Proportional hazards assumptions were assessed by a test 
of the interaction between log (time metric) and each predictor (not violated). The 
linearity of age at the index encounter was assessed by a fractional polynomial 
technique (not violated).55 Furthermore, the plots for the coefficients of the age 
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categories generated from adding the age category as a covariate to the best 
fitting model were examined to examine whether age made an additional 
contribution to the best fitting models. 
The existence of influential outliers was examined by plotting the Scaled 
Score Residuals versus each predictor to identify subjects who may have 
influenced the value of a single coefficient and by plotting the likelihood 
displacement versus the Martingale Residual to identify subjects who may have 
influenced the vector of coefficients (no subjects were excluded).95 We also 
assessed 2-way interactions and co-linearity among the final predictors (not 
found). Model discrimination was assessed using the Harrell macro for Cox 
regression (the c-index),56 while goodness-of-fit (calibration) was assessed by 
the May-Hosmer method.57 In addition, 100 replications of bootstrapping using 
the unrestricted random sampling technique were used to validate the best fitting 
model internally; 95%CIs of the c-index were also reported.  
To help clinicians improve the management of their patients during the 
acute treatment phase, the final prognostic models for predicting 3-month VTE 
recurrence among all patients, and separately among patients without active 
cancer, were used to develop the 3-month risk score calculators based on 
methods previously used in published studies.58-62 The risk score was calculated 
as follows: the factor with the smallest logarithmic HR (natural log of HR) was 
assigned 1 point, with other factor scores based on the size of their estimates 
relative to the smallest logarithmic HR; Individual predictor scores were summed 
91 
 
to give a total risk score (on a 0-100 scale) for each patient. The accuracy of 
calibration was demonstrated by comparing predicted to observed risk (using the 
Kaplan-Meier method) over the full range of risk scores. The correlation of 
predicted risk generated by two risk calculators for the same patient was 
assessed.  
All analyses were performed using SAS 9.2 (SAS Institute Inc., Cary, NC) 
and statistical significance level was pre-specified as α=0.05 (two sided). 
 
4.4 Results 
Over the 10-year study period, a total of 2,989 WMSA residents were 
diagnosed with a first episode of acute PE±DVT (42%) or lower-extremity DVT 
alone (58%) . These patients were followed for a total of 5,836 person-years with 
mean follow-up duration of 23.4(±14.4) (median=30) months. Their mean age 
was 64.3(±18.0) years, 44% were men, and 94% were white. The proportions of 
cancer-associated, provoked, and unprovoked episodes of VTE were 17%, 43%, 
and 40%, respectively. Individual risk factors assessed during the index 
encounter are shown in Table 4.1.  
During the follow-up period, 329 patients developed a recurrent VTE; the 
Kaplan-Meier estimated CIRs of VTE recurrence were 5.1% within 3 months and 
15% within 3 years after the index event among all patients (Figure 4.1A). The 
CIRs of VTE recurrence among patients with active cancer, provoked, and 
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unprovoked VTE were 8.7%, 5.2%, and 3.8% within 3 months and 25%, 13%, 
and 13%, within 3 years, respectively (Figure 4.1B).  
Predicting Recurrence within 3 Years for All Patients 
HRs and 95% CIs generated from unadjusted Cox regression models  for 
more than 50 potential risk factors  for recurrent VTE within 3 years are 
presented in Table 4.2. Advanced age, active cancer (with/without 
chemotherapy), diabetes mellitus, a hypercoaguable state (as indicated in 
medical records), myeloproliferative disease, superficial thrombophlebitis, 
varicose vein stripping, prior nonsurgical-related hospitalization before index 
event, admission to hospital at the pateint’s index encounter, and inferior vena 
cava (IVC) filter placement were associated with an increased risk of recurrence 
during this period; undergoing surgery before the  index event was associated 
with a decreased long-term risk of recurrence (Table 4.2). In the mulivariable Cox 
regression analyses, six factors were identified as independent predictors of VTE 
recurrence during the 3-year follow-up (c-index 0.616[0.614-0.619]; Figure 4.2A): 
active cancer with/without chemo, hypercoaguable state, superficical 
thrombophlebitis, varicose vein stripping, IVC filter placement, and prior sugery 
within 3 months of the index event. 
Predicting Recurrence within 3 Months for All Patients 
The unadjusted Cox regression model identified active cancer 
(with/without chemotherapy), hypercoaguable state, major trauma, varicose vein 
stripping, prior nonsurgical-related hospitalization before the index event, taking 
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an anticoagulant at admission, and receipt of thrombolytic therapy or inferior 
vena cava (IVC) filter placement to be  associated with an increased risk of 
recurrence within 3 months after the index event; receipt of subcutaneous low-
molecular-weight heparin (LMWH) or warfarin during the initial treatment period 
was associated with decreased short-term risk of recurrence (Table 4.2).  
 In the mulivariable Cox regression analyses, seven factors were identified 
as independent predictors of VTE recurrence during the first 3 months after the 
index event (c-index 0.670[0.668-0.675], Figure 4.2B): active cancer, major 
trauma within 3 months before index event, hypercoaguable state, varicose vein 
stripping, diagnosed with DVT-alone at index encounter, taking anticoagulant 
therapy at admission, and  IVC filter placement.    
 Separating the independent predictor “active cancer” into with/without 
chemotherapy categories did not improve the model performance (c-index 
decreased 0.004), and the HRs of active cancer with chemotherapy and active 
cancer without chemotherapy were 1.70 (1.01-2.86) and 1.62 (0.98-2.69) versus 
no-cancer, respectively. Thus, ‘active cancer (with/without chemotherapy)’ was 
used as a covariate in the final predictive model (HR: 1.66 [1.12-2.45]).   
Predicting Recurrence within 3 Months for Patients without Active Cancer 
Among 2,492 patients without active cancer (106 recurrent episodes at  3 
months), the risk factors associated with 3 month recurrence were similar to 
those identified for all patients from the unadjusted Cox regression analysis, with 
the exception that stroke was associated with an increased risk of recurrence 
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and receiving treatment with warfarin was no longer associated with a decreased 
short-term risk of recurrence (Table 4.3). In the multivariable Cox regression 
analyses, five factors were identified as independent predictors of recurrence 
during the first 3 months after the index event (c-index 0.648 [0.646-0.654], 
Figure 4.2C): major trauma within 3 months before index event, a 
hypercoaguable state, varicose vein stripping, taking anticoagulants at 
admission, and  IVC filter placement. The index diagnosis (PE±DVT vs. DVT 
alone) was no longer an independent predictor compared with the prognostic 
model based on all patients.  
Predicting Recurrence within 3 Months for Patients with Active Cancer 
Among 497 patients with active cancer (35 recurrent episodes of VTE at 3 
months), only a family history of VTE and receiving stockings during the initial 
treatment period were significiantly associated with increasing 3 month risk of 
VTE recurrence based on unadjusted Cox regression findings  (Table 4.3). In the 
multivariable adjusted regression model, only a family history of VTE was 
identified as an independent predictor of recurrent VTE. Therefore, a risk score 
calculator was not developed for these patients.  
Age and VTE Recurrence 
The unadjusted Cox regression model  indicated that the HR of age per 
10-year increase was 1.07 (1.00-1.13) for VTE recurrence during  the entire 3 
year follow-up period (Table 4.2), 1.03 (0.94-1.13) for VTE recurrence within the 
first 3 months after the index event among all patients (Table 4.2), and 0.99 
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(0.89-1.09) for VTE recurrence within the first 3 months after the index event 
among patients without active cancer (Table 4.3). The multivariable adjusted Cox 
regression model indicated that age was neither an independent predictor for 
VTE recurrence within 3 months nor within 3 years after the index VTE event. In 
addition, the plots of the coefficients of the age categories generated by adding 
age category as a covariate into the best fitting models provided convincing 
evidence that, after taking into account the contributions of the other predictors in 
the best fitting model, age made no apparent contribution to predict VTE 
recurrence (Figure 4.3 A/B/C). 
Risk Score Calculators for Predicting 3-month VTE Recurrence 
A risk calculator was developed based on the seven independent 
predictors of VTE recurrence during the first 3 months after the index event 
among all patients. A total risk score (range 0-100 points) was obtained by 
summing the individual points for each predictor (Figure 4.4A). Based on the 
predicted risk, each risk predictor was classified into one or two levels (Class-A 
and Class-B, Figure 4.4.A). The predicted versus observed probability of VTE 
recurrence within 3 months, based on the total risk score category, showed   
good model calibration (Figure 4.4B). Figure 4.4C provided a visual illustration of 
the predicted probability based on the number of risk predictors and risk class.  
Another risk calculator was developed based on the five independent 
predictors of VTE recurrence during the first 3 months after the index event 
among patients without active cancer. A total risk score (range 0-100 points) was 
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obtained by summing the individual points for each of the predictors (Figure 
4.5A). Based on the predicted risk, each risk predictor was classified into one or 
two levels (Class-A and Class-B, Figure 4.5.A).The predicted versus observed 
probability of VTE recurrence within 3 months based on the total risk score 
category, and a visual decision tree based on the number of risk predictors and 
risk class, are illustrated in Figures 4.5B and 4.5C. 
We used the two risk calculators to generate two different predicted risks 
for  VTE recurrence for the same l patient without active cancer. In comparing the 
individual patient-level predicted risk of VTE recurrence generated by the two 
caculators, the r-square value was  0.83 (Figure 4.6), which indicated excellent 
correlation between the two calculators. 
 
4.5 Discussion 
We assessed the cumulative risk of VTE recurrence over a 3-year follow-
up period among residents of central MA diagnosed with a first-time episode of 
PE and/or lower-extremity DVT between 1999 and 2009 on a biennial basis. 
Despite advances in treatment, the 3-year CIR of VTE recurrence remained high 
in our population-based surveillance study, particularly among patients with 
active cancer. We systematically evaluated a large number of patient 
characteristics assessed during the patient’s  index encounter as potential risk 
predictors, and identified several  independent predictors of VTE recurrence 
97 
 
during the acute (3 month) treatment phase  and the long-term (3 year) follow-up 
window among patients diagnosed with a first confirmed episode of  VTE. 
Cumulative Risk of VTE Recurrence 
The CIRs of VTE recurrence in our study were higher than have been 
observed in  previous randomized clinical trials (RCTs) of VTE treatment.84 
These differences are likely related, in part, to inclusion criteria employed in the 
RCTs, resulting in a more narrowly defined “healthier” population. In addition, 
anticoagulant therapy is monitored more carefully in RCTs than in an 
uncontrolled community practice setting. Indeed, compared with  our findings, 
published observational studies have reported higher rates of recurrent VTE after 
an acute episode of VTE: 8% at 3 months and 20% at 3 years.31, 85  
After stratifying the patient’s index event into cancer-associated, provoked, 
and unprovoked VTE, the CIR of VTE recurrence was highest among patients 
with active cancer. Consistent with our findings, a prospective analysis of more 
than 800 patients with VTE, in whom 181 had known cancer at the time of study 
entry, revealed that the 1-year cumulative incidence of recurrent VTE was three-
fold higher in patients with cancer compared to those without.92  
 Historically, the recurrence rates after an acute episode of VTE among 
cancer patients has been higher than among patients without cancer.48-49, 87 Our 
estimated 3-year CIR of recurrent VTE among individuals with a provoked VTE 
was similar to the 3-year CIR generated from a population-based cohort study 
including all non-cancer-associated first-time VTE patients identified through the 
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United Kingdom (UK) primary care database between 2001 and 2011.91 In this 
UK study, the 3-year CIR of recurrent VTE was approximately 5% higher among 
patients with an unprovoked index VTE compared to those with a provoked 
episode.91 However, in our study, we found no suggestion of a difference in the 
recurrence rate between these two groups. This may be related to the use of an 
administrative database in the UK study and their inability to robustly differentiate 
between index and recurrent events, or to document different practice patterns in 
managing persons with unprovoked VTE. Indeed, other studies have also 
reported that approximately 4% of patients with unprovoked VTE develop a 
recurrence within 6 months,96-97 which is similar to our findings. 
Independent Predictors of VTE Recurrence  
After systematically evaluating a large number of characteristics assessed 
during the index encounter, it was not surprising that active cancer was strongly 
associated with an increased risk of VTE recurrence over  both the short- and 
long-term follow-up. Based on relative model chi-square values (indicating the 
relative predictive strength of a model’s risk predictors), patients with active 
cancer undergoing chemotherapy were at greatest risk for recurrence during our 
long-term follow-up. In a population-based observational study conducted among 
residents of Olmsted County, Minnesota, over the period  1976 to 1990, patients 
with cancer receiving chemotherapy had a more than four-fold increased risk of 
VTE recurrence within 10 years after the index event, while cancer patients not 
taking chemotherapy had a two-fold increased risk, compared to patients without 
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cancer.31 However, during a 3-month follow-up, we observed no additional 
increase in the risk of VTE recurrence due to receipt of chemotherapy in patients 
with active cancer. We hypothesize that VTE patients with active cancer who 
were not undergoing chemotherapy may have received as much clinical 
monitoring as those undergoing chemotherapy during the acute VTE treatment 
phase consistent with the recommendations of contemporary guidelines. 48  
With regard to the remaining independent predictors in both the short-term 
and long-term prediction models, these predictors are consistent with the three 
underlying factors associated with the development of venous thrombi that were 
first  proposed by Virchow in 1884: vascular endothelial damage(i.e., varicose 
vein stripping, superficial thrombophlebitis), stasis of blood flow, and blood 
hypercoagulabiltiy (i.e., hypercoagulable state).23 
Based on relative model chi-square values, IVC filter placement was a 
strong independent predictor for VTE recurrence over  both short and long-term 
follow-up. This finding is supported by data in a recent expert concensus review 
that IVC placement may increase the risk of early VTE recurrence by as much as 
50%.49 Patients who received an IVC filter may have been unable to receive 
anticoagulant treatment due to contraindications to anticoagulation.97 Our prior 
publication demonstrated that patients who received an IVC filter were older and 
had more comorbidities.98 These patients require special attention, as an IVC 
filter alone is inadequate therapy for acute VTE.49   
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 The role of “transient” risk factors (associated with a reduced risk of 
recurrence in the long-term or increased risk of recurrence in the short-term) is 
widely acknowledged.48, 87 We found that patients who had undergone recent 
surgery within 3 months before index event had an approximate 30% reduction in 
the risk for recurrence during long-term follow-up after the index event compared 
with  those who had not undergone surgery as the risk of subsequent recurrence 
declines  after the patient recovers from  surgery, which is consistant with the 
previously published literature.29 49 48, 87 In addition, we found that patients with a  
recent major trauma had a two-fold increased risk of VTE recurrence during the 
first 3 months. Most of these patients were likely still in recovery from their major 
trauma during the 3 months after the index event, which could prolong the period 
of VTE risk, particularly due to prolonged immobility.23 
  In recent publications, there are conflicting findings as to whether the type 
of the  index event (PE vs. DVT) is a predictor of VTE recurrence, irrespective of 
the  duration of follow-up ;49 these include no increased risk by type of VTE 
event,31, 96 or an increased risk for patients with incident PE84, 87 or proximal 
DVT.85 In our study, the index diagnosis (PE±DVT vs. DVT alone) was not an 
independent predictor of recurrence during long-term follow-up. However, 
patients diagnosed with DVT alone had an approximate  40% higher risk for 
developing a recurrence over the first 3-months of follow-up compared with 
patients diagnosed with PE±DVT based on the model built on all patients.  
  This finding may be explained by the higher 30-day mortality rate among 
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PE patients compared with patients who had DVT alone,18 as a greater 
proportion died before they had the opportunity to develop a recurrence. On the 
other hand, patients with DVT alone may have received less treatment or less 
effective treatment. In a prior publication, we showed that nearly 20% of patients 
with DVT alone did not receive either unfractionated heparin or low-molecular-
weight heparin during acute treatment compared with 12% among the PE±DVT 
group.18 In addition, an index diagnosis of VTE was the only independent 
predictor of 3-month recurrence that dropped out after we stratified patients into 
those with and without active cancer. This may be due to insufficient statistical 
power or to unmeasured and/or competing clinical factors that overpowered the 
VTE diagnosis at the time of the index encounter among patients without active 
cancer. 
Taking anticoagulant therapy at admission was idenfied as an 
independent predictor for increased risk of VTE recurrence within 3 months, 
which could be a proxy for other unmeasured risk factors, including 
commorbidities and genetic predisposition. Historically, increasing age has been 
considered to be a factor associated with higher incidence rates of VTE in the 
general population.3, 5, 23, 74 However, there are conflicting findings as to whether 
age is an independent predictor of VTE recurrence in the published literature. 
While some studies indicate that advancing age is associated with an increased  
risk of VTE recurrence,49, 93 some studies indicate that increasing age is 
associated with a decreasing risk of VTE recurrence.99 94 Moreover, some 
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studies did not identify age as an independent predictor of VTE recurrence after 
an acute episode of VTE,89 90, 100 similar to the findings observed in our study. 
These discrepancies could be related to variations in study design, the 
inclusion/exclusion criteria of cohort selection, incomplete documentation of the 
physicians examination for clinical VTE risk factors, and duration of follow-up. 
Further studies are needed to clarify the reasons for these observed 
discrepancies.101 
 
Risk Score Calculators for Predicting VTE Recurrence within 3 Months after the 
Index Event 
Realizing that time-dependent characteristics may change over the course 
of long-term follow-up, we developed risk score calculators based solely on our 
3-month prediction models, separately for all patients with first-time VTE and for 
the subset of persons without active cancer. Our intent was to develop a risk 
assessment tool for use at the index encounter to enable clinicians to tailor 
individual patient management practices during acute VTE treatment. Our risk 
calculators included variables that are readily available to clinicians and use a 
simple point system to estimate the risk of VTE recurrence.    
 Although the results of any prediction models are only as generalizable to 
populations similar to the one from which they were derived, we believe that our 
models are robust, based on our population-based study design, the 
comprehensive list of patient and clinical characteristics assessed during the 
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index encounter, and internal validation. We hope that our calculator may serve 
as a tool to assist clinicians at the time of the index encounter to better determine 
the optimum frequency of subsequent clinical surveillance and the appropriate 
anticoagulant agents after initial treatment at clinical facilities. Our risk calculators 
differ from currently available calculators that are focused on information 
assessed at the end of the acute treatment phase and are only applicable to 
either cancer-associated or unprovoked VTE.89-90, 94, 102 
 Our sensitivity analyses indicate that our final risk calculator derived from 
all patients with first-time VTE has excellent correlation with a more limited risk 
calculator that was derived solely from patients without active cancer. Thus, our 
risk calculator based on all patients seems the best choice, based on its better 
discrimination (c-index 0.67 vs. 0.65) and the practical advantage of using a 
single, broad model at the bedside for all patients with an initial confirmed VTE. 
Study Strengths and Limitations 
This study employed population-based surveillance methods to 
systematically monitor the clinical epidemiology of VTE among residents of 
central MA. We conducted broad screening for cases of VTE using multiple 
databases, validated each potential case of VTE, and performed regular chart 
audits; nonetheless, we recognize that we may have missed some cases of 
asymptomatic VTE. Due to low autopsy rates in the WMSA, and the limited 
validity of death-certificate data,3, 7 only clinically recognized cases of acute VTE 
were described and some cases of fatal PE could have been missed. Consistent 
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with the design and results of other observational studies, unmeasured, or 
inadequately measured variables may have impacted our findings, despite the 
inclusion of more than fifty potential prognostic factors assessed during the index 
encounter. Unmeasured variables that may have impacted our findings include 
unknown duration of anticoagulant treatment after initial treatment in clinical 
facility and any changes in dose or type of medication subsequent to initial 
treatment prescriptions. Further refinement of our prediction model may require 
the inclusion of additional time-dependent risk factors and perhaps biomarkers to 
increase precision; and of anticoagulation strategy and adherence to it at 3 
months.  Although we have conducted internal validation on our findings to show 
that our best fitting models are robust, we recognize that no study can effectively 
validate itself: “a true evaluation of generalizability requires evaluation on data 
from elsewhere”.63 Therefore, external validations of our models are needed to 
fully assess the model performance. Nevertheless, we believe that our current 
risk score discrimination allows separation of patients into broad, clinically 
meaningful categories and provides guidance for improving decisions on patient 
management from the index encounter through the patient’s acute treatment. 
 
4.6 Conclusions 
This population-based study in residents of central Massachusetts has 
quantified the risk of developing a recurrent episode of VTE over a 3-year follow-
up among patients with a first episode of VTE. We have identified independent 
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predictors of recurrence that will be useful in the design of future studies focused 
on estimating the true risks and benefits associated with VTE treatment at the 
individual patient-level. Our risk score calculators are designed to be used during 
the initial treatment phase for predicting recurrence during the entire acute 
treatment phase.  This may help clinicians to determine the optimal frequency of 
subsequent clinical surveillance and the appropriate outpatient treatment of VTE.  
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4.7 Tables and figures 
Table 4.1 Patient Characteristics Assessed during Index Encounter among All Patients 
Diagnosed with First-Time VTE 
 
Characteristics All patients 
(N=2989) 
Demographic characteristics  
Age, y   
Mean±SD 64.3±18.0 
Median (IQR) 67 (51-79) 
Men, n (%) 1319 (44.1) 
White, n (%) 2712 (94.2) 
BMI, kg/m2  
<25  663 (30.8) 
25-30  661 (30.7) 
>30 826 (38.4) 
Current smoker, including quitting within 3 months 508 (17.0) 
Recenta medical history, n (%)  
Cancer (active) 497 (16.6) 
With chemotherapy 254 (51.1) 
Without chemotherapy 243 (48.9) 
Chronic obstructive pulmonary disease 633 (21.2) 
Congestive heart failure 316 (10.6) 
Diabetes mellitus 579 (19.4) 
Family history of VTE 141 (4.7) 
Hypercoagulable state 42 (1.4) 
Hyperlipidemia 1063 (35.6) 
Hypertension 1703 (57.0) 
Inflammatory bowel disease (Crohn’s/ulcerative colitis) 75 (2.5) 
Infection 723 (24.2) 
Liver disease 101 (3.4) 
Major fracture 237 (7.9) 
Major trauma 239 (8.0) 
Mixed connective tissue disease (rheumatoid arthritis, lupus, 
scleroderma, Sjogren’s) 
152 (5.1) 
Myeloproliferative disease 25 (0.8) 
Myocardial infarction 135 (4.5) 
Neurologic disease 246 (8.2) 
Paralysis of lower extremity 131 (4.4) 
Peripheral artery disease 242 (8.1) 
Pulmonary hypertension 136 (4.6) 
Renal disease 347 (11.6) 
Stroke 123 (4.1) 
Superficial thrombophlebitis 151 (5.1) 
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Characteristics All patients 
(N=2989) 
Varicose veins 262 (8.8) 
Varicose vein stripping 117 (3.9) 
HRT/oral contraceptives 232 (13.9) 
Statin therapy 671 (22.5) 
Bed rest >48 hours 1144 (38.3) 
Cardiac procedure 156 (5.2) 
Central venous catheter 384 (12.9) 
Discharged from intensive care unit  466 (15.6) 
Hospitalization due to nonsurgical illness before index event 949 (31.8) 
Intubation 535 (17.9) 
Surgery before index event 786 (26.3) 
VTE characteristic, n (%)  
PE±DVT 1251 (41.9) 
Lower extremity DVT alone 1738 (58.1) 
Type of VTE event  
Cancer associated 497 (16.6) 
Provoked (noncancer-associated)b 1291 (43.2) 
Unprovokedc 1201 (40.2) 
Community presentingd 2299 (76.9) 
Admitted to hospital 2214 (74.1) 
Antithrombotic medication at index encounter, n (%)  
Antiplatelet 838 (28.0) 
Anticoagulant 121 (4.1) 
Acute treatmente   
Intravenous/subcutaneous unfractionated heparin 1284 (43.0) 
Subcutaneous low-molecular-weight heparin 1748 (58.5) 
Warfarin 2040 (68.3) 
Any anticoagulant therapyf 2601 (87.0) 
Inferior vena cava filter implanted prior/during index visit 379 (12.7) 
Stocking 58 (1.9) 
Thrombolytic therapy administered 1151 (38.5) 
Among patients admitted to hospital N=2214 
Length of stay, days   
Mean±SD 8.5±10.1 
Median (IQR) 5 (3-9) 
Hypercoagulable workup abnormal 162 (5.4) 
Patient discharged with subtherapeutic INR (<2.0) 828 (37.4) 
Any excessive INRs >3.0 prior to hospital discharge 429 (19.4) 
 
Abbreviations: BMI, body mass index; DVT, deep vein thrombosis; HRT, hormone replacement 
therapy; INR, international normalized ratio; IQR, inter-quartile range; PE, pulmonary embolism; 
SD, standard deviation; VTE, venous thromboembolism. 
a Within previous 3 months and prior to index VTE. 
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b History of surgical procedure, pregnancy, trauma, fracture, or hospitalization within 3 months 
prior to index visit. 
c Absence of any of the above “provoking” factors or active malignancy (cancer-associated). 
d Ambulatory patients presenting to all central Massachusetts hospitals with signs and symptoms 
consistent with VTE, or diagnosed with VTE within 24 hours of hospital presentation 
e Acute therapy in a health-care facility (inhospital/at discharge or ambulatory setting); may 
include more than one anticoagulant. 
f Intravenous/subcutaneous unfractionated heparin, subcutaneous low-molecular-weight heparin, 
Warfarin,other  
 
 
Table 4.1s Frequency of Recurrent Events after Index Encounter  
Index Event (N=2989) Recurrent Event after Index Event 
 within 3 months after Index Event 
 VTE (n=141) PE (n=32) DVT (n=119) 
PE only (n=729) 17 (2.3%) 4 (0.6%) 15 (2.1%) 
DVT only (n=1738) 93 (5.4%) 23 (1.3%) 74 (4.3%) 
PE and DVT (n=522) 31 (5.9%) 5 (1.0%) 30 (5.8%) 
 within 3 months after Index Event 
 VTE (N=141) PE (n=32) DVT (n=119) 
PE±DVT (n=1251) 48 (3.8%) 23 (1.3%) 74 (4.3%) 
DVT alone (n=1738) 93 (5.4%) 9 (0.7%) 45 (3.6%) 
 Recurrence within 3 years after Index Event 
 VTE (n=329) PE (n=88) DVT (n=281) 
PE only (n=729) 51 (7.0%)  19 (2.6%) 38 (5.2%) 
DVT only (n=1738) 208 (12.0%)  55 (3.2%) 178 (10.2%) 
PE and DVT (n=522) 70 (13.4%)  14 (2.7%) 65 (12.5%) 
 Recurrence within 3 years after Index Event 
 VTE (N=329) PE (n=88) DVT (n=281) 
PE±DVT (n=1251) 121 (9.7%)  33 (2.6%) 103 (8.2%) 
DVT alone (n=1738) 208 (12.0%)  55 (3.2%) 178 (10.2%) 
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Table 4.2 Patient Characteristics Associated with the Risk of Recurrence after Index VTE 
Event among All Patients Diagnosed with First-Time VTE (Unadjusted Cox Proportion 
Hazard Model) 
 
Characteristics Entire 3 years 
N=2989 
First 3 months 
N=2989 
# of recurrent VTEs 329 141 
 HR (95% CI) HR (95% CI) 
Demographic characteristics   
Age, y (per 10-y increment) 1.07 (1.00-1.13) 1.03 (0.94-1.13) 
Men 0.98 (0.79-1.22) 1.02 (0.73-1.43) 
White 0.80 (0.53-1.22) 0.99 (0.48-2.02) 
BMI, kg/m2 (ref: <25 kg/m2)   
25-30  0.85 (0.61-1.17) 1.01 (0.63-1.60) 
>30 0.81 (0.60-1.09) 0.70 (0.43-1.13) 
Current smoker, including quitting within 3 
months 
0.91 (0.70-1.21) 0.85 (0.53-1.35) 
Recenta medical history   
Cancer (active) (ref: none) 2.06 (1.58-2.69) 1.66 (1.14-2.44) 
With chemotherapy 2.63 (1.90-3.62) 1.79 (1.08-2.99) 
Without chemotherapy 1.53 (1.03-2.28) 1.92 (1.16-3.16) 
Chronic obstructive pulmonary disease 1.13 (0.86-1.48) 1.23 (0.84-1.81) 
Congestive heart failure 1.01 (0.68-1.50) 1.25 (0.76-2.05) 
Diabetes mellitus 1.32 (1.01-1.71) 1.13 (0.76-1.69) 
Family history of VTE 1.26 (0.82-1.94) 1.73 (0.93-3.20) 
Hypercoaguable state 2.71 (1.44-5.08) 3.28 (1.45-7.44) 
Hyperlipidemia 0.98 (0.78-1.23) 1.24 (0.89-1.74) 
Hypertension 1.23 (0.98-1.53) 1.12 (0.80-1.57) 
Inflammatory bowel disease 
(Crohn’s/ulcerative colitis) 
1.17 (0.60-2.27) 1.77 (0.78-4.02) 
Infection 1.03 (0.79-1.34) 0.92 (0.62-1.36) 
Liver disease 0.72 (0.34-1.53) 0.83 (0.31-2.25) 
Major fracture 0.69 (0.43-1.09) 0.88 (0.46-1.67) 
Major trauma 1.31 (0.93-1.87) 2.08 (1.31-3.31) 
Mixed connective tissue disease 
(rheumatoid arthritis, lupus, scleroderma, 
Sjogren’s) 
0.80 (0.46-1.40) 0.54 (0.20-1.46) 
Myeloproliferative disease 2.62 (1.17-5.87) 1.77 (0.44-7.14) 
Myocardial infarction 0.74 (0.39-1.38) 0.95 (0.42-2.15) 
Neurologic disease 0.97 (0.65-1.45) 1.24 (0.71-2.15) 
Paralysis of lower extremity 0.96 (0.55-1.67) 1.34 (0.65-2.72) 
Peripheral artery disease 1.20 (0.81-1.78) 0.87 (0.46-1.66) 
Pulmonary hypertension 1.02 (0.58-1.77) 0.77 (0.31-1.87) 
Renal disease 1.26 (0.90-1.78) 1.19 (0.74-1.94) 
Stroke 1.56 (0.96-2.54) 1.84 (0.97-3.51) 
Superficial thrombophlebitis 1.74 (1.18-2.56) 1.80 (0.99-3.25) 
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Characteristics Entire 3 years 
N=2989 
First 3 months 
N=2989 
# of recurrent VTEs 329 141 
 HR (95% CI) HR (95% CI) 
Varicose veins 1.14 (0.80-1.63) 1.07 (0.60-1.88) 
Varicose vein stripping 1.88 (1.22-2.90) 2.18 (1.18-4.03) 
HRT/oral contraceptives (among women) 0.90 (0.59-1.36) 1.02 (0.54-1.93) 
Statin therapy 0.97 (0.74-1.26) 1.01 (0.68-1.50) 
Bed rest >48 hours 0.88 (0.71-1.13) 0.97 (0.69-1.37) 
Cardiac procedure 0.67 (0.36-1.21) 0.67 (0.27-1.63) 
Central venous catheter 1.21 (0.87-1.78) 1.26 (0.80-1.98) 
Discharged from intensive care unit 0.96 (0.70-1.32) 1.23 (0.81-1.89) 
Hospitalization due to nonsurgical illness 
before index event 
1.30 (1.03-1.63) 1.49 (1.06-2.09) 
Intubation 0.93 (0.69-1.25) 1.14 (0.76-1.73) 
Surgery before index event 0.76 (0.59-0.98) 0.82 (0.55-1.22) 
VTE characteristic   
PE±DVT (ref: lower extremity DVT alone) 0.86 (0.69-1.08) 0.71 (0.50-1.01) 
Type of VTE event (ref: provoked 
[noncancer-associated])b 
  
Cancer associated 2.03 (1.52-2.72) 1.60 (1.06-2.43) 
Unprovokedc 0.97 (0.76-1.24) 0.76 (0.51-1.11) 
Community presentingd 0.84 (0.65-1.09) 0.90 (0.62-1.32) 
Admitted to hospital 1.37 (1.06-1.77) 1.30 (0.87-1.95) 
Antithrombotic medication at index 
encounter 
  
Antiplatelet 0.85 (0.66-1.10) 0.88 (0.60-1.29) 
Anticoagulant 1.62 (0.997-2.65) 2.26 (1.25-4.08) 
Acute treatmente    
Intravenous/subcutaneous unfractionated 
heparin 
1.08 (0.87-1.34) 1.08 (0.77-1.50) 
Subcutaneous low-molecular-weight 
heparin 
0.86 (0.69-1.07) 0.65 (0.47-0.91) 
Warfarin 0.82 (0.65-1.04) 0.70 (0.50-0.99) 
Any anticoagulant therapyf 0.83 (0.60-1.15) 0.62 (0.41-0.94) 
IVC filter implanted prior/during index visit 2.04 (1.54-2.70) 2.73 (1.89-3.95) 
Stocking 1.26 (0.62-2.54) 1.09 (0.35-3.42) 
Thrombolytic therapy administered 1.16 (0.93-1.45) 1.46 (1.05-2.04) 
Among patients admitted to hospital   
Length of stay (per 1-day increment)  1.003 (0.99-1.02) 1.02 (1.00-1.03) 
Hypercoagulable workup abnormal 0.95 (0.60-1.51) 1.20 (0.61-2.35) 
Patient discharged with subtherapeutic 
INR (<2.0) 
1.004 (0.80-1.26) 1.05 (0.74-1.49) 
Any excessive INRs >3.0 prior to hospital 
discharge 
0.87 (0.63-1.20) 0.93 (0.57-1.50) 
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Abbreviations: BMI, body mass index; CI, confidence interval; DVT, deep vein thrombosis; HR, 
hazard ratio; HRT, hormone replacement therapy; INR, international normalized ratio; IVC, 
inferior vena cava; PE, pulmonary embolism; ref., reference group; VTE, venous 
thromboembolism. 
a Within previous 3 months and prior to index VTE. 
b History of surgical procedure, pregnancy, trauma, fracture, or hospitalization within 3 months 
prior to index visit. 
c Absence of any of the above “provoking” factors or active malignancy (cancer-associated). 
d Ambulatory patients presenting to all central Massachusetts hospitals with signs and symptoms 
consistent with VTE, or diagnosed with VTE within 24 hours of hospital presentation 
e Acute therapy in a health-care facility (inhospital/at discharge or ambulatory setting); may 
include more than one anticoagulant 
f Intravenous/subcutaneous unfractionated heparin, subcutaneous low-molecular-weight heparin, 
Warfarin,other  
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Table 4.3 Patient Characteristics Associated with the Risk of Recurrence within 3 months 
after Index VTE Event Stratified by patients with/without active cancer (Unadjusted Cox 
Proportion Hazard Model) 
 
Characteristics Patients without 
active cancer 
N=2492 
Patients with 
active Cancer 
N=497 
VTE Recurrent within 3-month after index 106 35 
 HR (95% CI) HR (95% CI) 
Demographic characteristics   
Age, y (per 10-y increment) 0.99 (0.89-1.09) 1.04 (0.81-1.35) 
Men 0.88 (0.60-1.30) 1.55 (0.79-3.02) 
White 1.23 (0.50-3.02) 0.56 (0.17-1.84) 
BMI, kg/m2 (ref: <25 kg/m2)   
25-30  0.96 (0.55-1.66) 1.25 (0.54-2.88) 
>30 0.79 (0.46-1.36) 0.46 (0.15-1.44) 
Current smoker, including quitting within 3 
months 
0.71 (0.41-1.25) 1.45 (0.63-3.31) 
Recenta medical history   
Cancer (active) (ref: none) NA NA 
With chemotherapy NA 0.98 (0.51-1.90) 
Without chemotherapy NA reference 
Chronic obstructive pulmonary disease 1.51 (0.99-2.31) 0.55 (0.21-1.41) 
Congestive heart failure 1.46 (0.86-2.47) 0.65 (0.16-2.69) 
Diabetes mellitus 1.21 (0.76-1.92) 0.87 (0.38-1.98) 
Family history of VTE 1.27 (0.59-2.73) 8.18 (2.88-23.20) 
Hypercoaguable state 3.66 (1.49-8.98) 2.16 (0.30-15.81) 
Hyperlipidemia 1.23 (0.84-1.82) 1.21 (0.62-2.36) 
Hypertension 1.17 (0.80-1.73) 0.87 (0.44-1.70) 
Inflammatory bowel disease (Crohn’s/ulcerative 
colitis) 
2.28 (0.999-5.19) 0 
Infection 0.96 (0.61-1.50) 0.80 (0.35-1.84) 
Liver disease 0.66 (0.16-2.66) 0.92 (0.22-3.85) 
Major fracture 1.07 (0.56-2.06) 0 
Major trauma 2.40 (1.48-3.91) 1.17 (0.16-8.55) 
Mixed connective tissue disease (rheumatoid 
arthritis, lupus, scleroderma, Sjogren’s) 
0.69 (0.25-1.86) 0 
Myeloproliferative disease 2.64 (0.65-10.69) 0 
Myocardial infarction 1.19 (0.52-2.72) 0 
Neurologic disease 1.48 (0.83-2.64) 0.46 (0.06-3.34) 
Paralysis of lower extremity 1.69 (0.82-3.48) 0 
Peripheral artery disease 0.90 (0.44-1.86) 0.81 (0.19-3.37) 
Pulmonary hypertension 0.78 (0.29-2.12) 0.79 (0.11-5.74) 
Renal disease 1.28 (0.74-2.21) 0.93 (0.33-2.63) 
Stroke 2.18 (1.10-4.32) 0.82 (0.11-6.01) 
Superficial thrombophlebitis 1.92 (0.999-3.67) 1.57 (0.38-6.52) 
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Characteristics Patients without 
active cancer 
N=2492 
Patients with 
active Cancer 
N=497 
VTE Recurrent within 3-month after index 106 35 
 HR (95% CI) HR (95% CI) 
Varicose veins 1.02 (0.53-1.96) 1.46 (0.45-4.78) 
Varicose vein stripping 2.37 (1.20-4.69) 1.59 (0.38-6.62) 
HRT/oral contraceptives  0.87 (0.41-1.82) 1.98 (0.56-7.03) 
Statin therapy 0.84 (0.52-1.37) 1.46 (0.73-2.94) 
Bed rest >48 hours 1.16 (0.79-1.71) 0.54 (0.25-1.19) 
Cardiac procedure 0.83 (0.34-2.03) 0 
Central venous catheter 1.52 (0.90-2.55) 0.62 (0.24-1.60) 
Discharged from intensive care unit 1.33 (0.83-2.15) 0.95 (0.37-2.44) 
Hospitalization due to nonsurgical illness 
before index event 
1.62 (1.10-2.39) 0.71 (0.36-1.42) 
Intubation 1.26 (0.79-2.02) 0.78 (0.32-1.87) 
Surgery before index event 0.83 (0.52-1.31) 0.73 (0.34-1.55) 
VTE characteristic   
PE±DVT (ref: lower extremity DVT alone) 0.68 (0.45-1.03) 0.72 (0.36-1.41) 
Type of VTE event (ref: provoked [noncancer-
associated])b 
  
Cancer associated NA NA 
Unprovokedc 0.76 (0.49-1.16) NA 
Community presentingd 0.89 (0.54-1.47) 1.77 (0.73-4.26) 
Admitted to hospital 1.26 (0.80-1.99) 1.32 (0.55-3.19) 
Antithrombotic medication at index 
encounter 
  
Antiplatelet 0.88 (0.57-1.35) 0.99 (0.45-2.17) 
Anticoagulant 2.74 (1.43-5.25) 1.05 (0.25-4.37) 
Acute treatmente    
Intravenous/subcutaneous unfractionated 
heparin 
1.10 (0.75-1.62) 0.996 (0.51-1.94) 
Subcutaneous low-molecular-weight heparin 0.65 (0.45-0.96) 0.68 (0.35-1.33) 
Warfarin 0.76 (0.51-1.13) 1.23 (0.63-2.42) 
Any anticoagulant therapyf 0.55 (0.34-0.89) 0.94 (0.39-2.26) 
IVC filter implanted prior/during index visit 3.46 (2.28-5.24) 1.11 (0.48-2.53) 
Stocking 0.44 (0.06-3.12) 5.88 (1.41-24.50) 
Thrombolytic therapy administered 1.47 (1.01-2.16) 1.49 (0.76-2.89) 
Among patients admitted to hospital   
Length of stay (per 1-day increment)  1.02 (1.01-1.04) 0.99 (0.94-1.04) 
Hypercoagulable workup abnormal 1.41 (0.71-2.79) 0 
Patient discharged with subtherapeutic INR 
(<2.0) 
1.11 (0.75-1.66) 0.95 (0.44-2.02) 
Any excessive INRs >3.0 prior to hospital 
discharge 
0.84 (0.47-1.49) 1.21 (0.50-2.90) 
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Abbreviations: BMI, body mass index; CI, confidence interval; DVT, deep vein thrombosis; HR, 
hazard ratio; HRT, hormone replacement therapy; INR, international normalized ratio; IVC, 
inferior vena cava; PE, pulmonary embolism; ref., reference group; VTE, venous 
thromboembolism. 
a Within previous 3 months and prior to index VTE. 
b History of surgical procedure, pregnancy, trauma, fracture, or hospitalization within 3 months 
prior to index visit. 
c Absence of any of the above “provoking” factors or active malignancy (cancer-associated). 
d Ambulatory patients presenting to all central Massachusetts hospitals with signs and symptoms 
consistent with VTE, or diagnosed with VTE within 24 hours of hospital presentation 
e Acute therapy in a health-care facility (inhospital/at discharge or ambulatory setting); may 
include more than one anticoagulant 
f Intravenous/subcutaneous unfractionated heparin, subcutaneous low-molecular-weight heparin, 
Warfarin,other 
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Figure 4.1 Kaplan-Meier estimates of cumulative recurrence of VTE among WMSA 
residents with a first-time VTE diagnosed from 1999 through 2009.  
VTE: venous thromboembolism; WMSA: Worcester, Massachusetts, metropolitan statistical area. 
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Figure 4.2 Multivariable Cox Proportional Hazard Regression of Independent Predictors of 
VTE recurrence among WMSA residents with a first-time VTE diagnosed from 1999 
through 2009.  
VTE: venous thromboembolism; WMSA: Worcester, Massachusetts, metropolitan statistical area. 
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Figure 4.3 Plots for the coefficients of age categories generated by adding age category as 
a covariate in the best fitting models  
VTE: venous thromboembolism  
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Figure 4.4 Risk Score Calculator for predicting VTE recurrence during first 3 months after 
index event among all patients 
VTE: venous thromboembolism 
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Figure 4.5 Risk Score Calculator for predicting VTE recurrence during first 3 months after 
index event among patients without active cancer 
VTE: venous thromboembolism 
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Figure 4.6 Predicted risk of 3-month VTE recurrence for the same patients generated by 
two Risk Score Calculators  
VTE: venous thromboembolism 
Each data point represents individual patient without active cancer 
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Chapter V. Conclusions 
    
5.1 Summary of findings 
The primary objectives of this dissertation were to examine contemporary 
trends in the epidemiology of clinically recognized VTE and to assess the risk of 
recurrence, and factors associated with a recurrent event, after a first (incident) 
episode of VTE from a potentially more generalizable population-based 
perspective. 
Among 5,025 WMSA residents diagnosed with acute PE and/or lower-
extremity DVT during 9 annual periods between 1985 and 2009, 46% were men, 
95% were white, and their mean age was 65 years old. The age- and sex-
adjusted annual event rates for first-time VTE increased from 73 (95% CI 64–82) 
per 100,000 in 1985/1986 to 133 (122–143) in 2009, due chiefly to an increase in 
PE. The annual event  rate of recurrent VTE decreased from 39 (32–45) in 
1985/1986 to 19 (15–23) in 2003, and then increased to 35 (29–40) in 2009. 
There was an increasing trend in the use of non-invasive diagnostic testing in this 
population during the years under study, with about half of tests being invasive in 
1985/1986 and almost all being non-invasive by 2009. The proportion of patients 
with community-presenting VTE remained approximately 80% over time among 
patients presenting with first-time VTE. Treatment of VTE shifted from in-hospital 
treatment with warfarin and unfractionated heparin towards out-patient treatment 
with low-molecular-weight heparin and newer anticoagulants. 
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Among the 2,334 patients who were diagnosed with first-time community-
presenting VTE between 1999 and 2009, 43% had either surgery or a non-
surgical-related hospitalization during the 3 months preceding the index episode 
of VTE. Among patients who underwent prior surgery, the proportion who 
received perioperative VTE prophylaxis increased from 50% in 1999 to 76% in 
2009, primarily reflecting an increase in the receipt of pharmacologic prophylaxis. 
Among patients who had a prior non-surgical-related hospitalization, the 
proportion who received thromboprophylaxis did not vary over time, remaining 
consistently over 80%. The proportion of patients with provoked VTE decreased 
during the years under study concomitant with  increases in the proportion of 
individuals with unprovoked VTE. 
Among patients diagnosed with first-time community-presenting VTE 
between 1999 and 2009, the 3-year cumulative event rates of key outcomes after 
their  index VTE decreased, including all-cause mortality (41%-26%), major 
bleeding (12%-6%), and recurrent VTE (17%-9%). Overall, however, the 
cumulative incidence rates of recurrence within 3-years after a first episode of 
acute VTE remained at 15%, which were particularly high among patients with 
active-cancer (25%) compared to patients with provoked (13%) or unprovoked 
VTE (13%). In the mulivariable Cox regression analyses, 6 factors were identified 
as independent predictors of VTE recurrence during the entire 3-year follow-up 
period (c-index 0.62) and 7 independent predictors were identified for predicting 
risk of VTE recurrence during the first 3-months after a first-time acute episode of 
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VTE (c-index 0.69). Active-cancer (with/without chemotherapy), a  
hypercoagulable state, varicose vein stripping, and Inferior vena cava filter 
placement were indepedant predictors of recurrence during short- (3-month) and 
long-term (3-year) follow-up after first-time VTE. Risk caculators were developed 
based on the 3-month prognostic model among all patients and separately in  
patients without active cancer. These risk scores could assist clinicians at the 
time of the index encounter to better determine the appropriate timing of further 
clinical surveillance and the appropriate duration of outpatient treatment to 
prevent recurrent episodes of VTE.   
 
5.2 Study strengths and limitations 
The Worcester VTE study employed rigorous population-based 
surveillance methods to describe the clinical epidemiology of acute VTE and prior 
prophylaxis use among individuals residing in the WMSA. Although we 
conducted broad screening for cases of VTE using multiple databases, validated 
each potential case of VTE, and performed regular chart audits, it is possible that 
this study may have missed some cases. Owing to low autopsy rates in the 
WMSA, and the limited validity of death-certificate data,3, 7  only clinically 
recognized cases of acute VTE were described and some cases of fatal PE 
could have been missed. Further, regional differences may exist in the diagnostic 
workup of patients presenting with signs and symptoms of VTE. Since the WMSA 
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is predominantly a white population, additional population-based studies in 
minority populations are needed.  
In keeping with the findings from other observational studies, unmeasured 
variables may have impacted our findings. For example, we did not collect 
information on the use of anticoagulation beyond what was recommended 
immediately after the index VTE; therefore, we could not assess the impact of 
use of various anticoagulation strategies, including the duration of therapy, on 
our study outcomes. Further refinement of our prognostic model may require the 
inclusion of additional risk factors and biomarkers to increase its precision; and of 
anticoagulation strategy and adherence to it at 3 months. Nevertheless, we 
believe that our current risk score discrimination allows separation of patients into 
broad categories that are clinically meaningful and may provide novel guidance 
that is relevant for improving decisions on patient management from the index 
encounter through the patient’s phase of acute treatment. 
 
5.3 Implications and future research directions 
Despite advances in the identification, prophylaxis, and treatment of 
pateinst with VTE  between 1985 and 2009, the results of this dissertation 
indicate that the disease burden from VTE in residents of central Massachusetts 
remains high, with a trend towards increasing frequency of these events. While 
these increases may be partially due to increased sensitivity of diagnostic 
methods, especially for PE, they also imply that current prevention and treatment 
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strategies are less than optimal. The findings of an increase in the proportion of 
patients with unprovoked VTE indicate the need to better understand factors 
affecting the development of VTE in the community setting and to identify novel 
risk factors for this thrombotic disorder.  
 Although the decreasing frequency of major adverse outcomes in our 
study population between 1999 and 2009 was encouraging, mortality, major 
bleeding, and recurrence rates remained high among WMSA residents 
diagnosed with first-time community-presenting VTE. In particular, the 3-year 
cumulative recurrent rate of VTE after a first acute episode of VTE was doubled 
among patients with active cancer compared to patients without active cancer; 
these findings suggest the need for subsequent intervention studies focused on 
patients with cancer, particularly those undergoing chemotherapy. The 
independent predictors of recurrence identified in this dissertation will be useful in 
the design of future studies focused on estimating the true risks and benefits 
associated with VTE treatment at the individual patient-level. Risk calculators are 
designed to be used at the time of initial treatment for predicting the likelihood of 
recurrence during the entire 3-month acute treatment phase and may help 
clinicians to determine the subsequent frequency of clinical surveillance and the 
appropriate outpatient treatment of VTE. 
In conclusion, the Worcester VTE study provides a unique opportunity to 
examine secular trends in the magnitude, characteristics, diagnostic workup, 
treatment patterns, and long-term outcomes associated with VTE from the 
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perspective of a well-characterized population. This information is sorely lacking 
in the published literature. The findings of this dissertation set the stage for the 
design and systematic assessment of interventions designed to enhance the use 
of current management practices with the goal of favorably influencing the long-
term outcomes and quality of life of patients with VTE. 
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